



HEDG

HEALTH, ECONOMETRICS AND DATA GROUP

THE UNIVERSITY *of York*

WP 23/10

The Impact of a Disease-Specific Health Insurance Reform on Mortality

Felipe Menares and Pablo Muñoz

August 2023

<http://www.york.ac.uk/economics/postgrad/herc/hedg/wps/>

The Impact of a Disease-Specific Health Insurance Reform on Mortality*

Felipe Menares
UC Berkeley

Pablo Muñoz
U. de Chile

Abstract

We study the impact of a healthcare reform that standardized procedures across health providers to guarantee the timely coverage of a set of diseases. Using the universe of death records from Chile and a difference-in-differences research design, we show that mortality from the diseases covered by this reform decreased by 4.4%. The impact was larger on deaths from diseases more amenable to health care, which decreased by 7.1%. Among inpatients with covered diseases, the reform led to a 6.9% decrease in deaths and a 15% increase in surgeries. Our results suggest that this reform increased life expectancy by 0.39 years, creating benefits that largely outweighed its costs.

Keywords: Health Insurance, Mortality, Health Reform

JEL Codes: I13, I14, I15, I18

*This version: July 2023. We are particularly indebted to William H. Dow, Ronald D. Lee, and Joshua R. Goldstein for their advice and support at different stages of this project. We want to thank Tatiana Reyes, Daniela Reyes, Sofia Jordan, Andrea Miranda-Gonzalez, Julio Rodriguez, Joel Ferguson, Matias Morales, Juan Pablo Atal, and Mathieu Pedemonte, and seminar participants at the Berkeley Demography Student Workshop, the Institute for Research in Market Imperfections and Public Policy (U. de Chile), and the Essen Health Economics Conference for valuable comments and suggestions. F. Menares acknowledge financial support from The John L. Simpson ABD Graduate Students Research Fellowships in Global, International and Area Studies (GIAS), Graduate Division, UC Berkeley. All remaining errors are our own. Felipe Menares, University of California at Berkeley, Department of Demography. Email: fmenares@berkeley.edu. Pablo Muñoz, Departamento de Ingeniería Industrial, Universidad de Chile. Email: pablomh@uchile.cl.

1 Introduction

Recent studies on healthcare reforms suggest beneficial mortality effects resulting from expansions in insurance coverage (Sommers, 2017; Goldin et al., 2020; Borgschulte and Vogler, 2020; Miller et al., 2021). Most of the existing research, however, has focused on the impact of expanding coverage to previously uninsured populations. Data limitations and lack of quasi-experimental variation in healthcare access that is *independent* of insurance type have limited our knowledge on the effects of alternative health reforms (Sabik and Lie, 2008; Moreno-Serra and Smith, 2012; Gruber and Sommers, 2019). We overcome this hurdle by studying Chile’s most significant health insurance reform in the past 30 years: the Explicit Healthcare Guarantees program (known as “GES” for its Spanish acronym), a policy that implemented a nationwide standardization of procedures across health providers to guarantee the timely coverage of a set of diseases.

Recognizing that coverage can differ depending on specific healthcare provisions, Chilean Congress approved a package of bills between 2002-2004 that established regulations and specific rules prioritizing the treatment of 56 health-related problems amenable to health care (heart attack, ischemic stroke, hypertension, diabetes, pneumonia, and specific cancers: breast, lymphoma, prostate, and testicular, among others). The approved legislation establishes that eligibility only depends on patients’ diagnosis and age and is independent of their income or type of insurance. In addition, the reform established specific and mandatory guidelines for providers defining a maximum time for detection, diagnosis, and treatment of the covered diseases (Missoni and Solimano, 2010). Since then, when a patient’s medical diagnosis is confirmed, they are assigned to a specific network to initiate treatment in accordance with the established guidelines. Given budget constraints, the diseases included *de jure* in the GES program were covered in a staggered fashion.

Since we only observe deaths and not the prevalence of each disease in the population, we estimate a staggered difference-in-differences using a Poisson model. Our main finding is that the reform led to a 4.4% reduction in deaths. Taken at face value, this number implies that lives saved due to reform coverage represent 2.7% of the total number of deaths (in 2003, the year before the reform), suggesting an increase in life expectancy large enough to have taken Chileans in 2003 forward to the mortality conditions of 2005 when life expectancy was 77.78 years. Reassuringly, estimates from an event study align with our parallel relative trends assumption and indicate that the impact of the reform persisted until the end of our analysis period. Moreover, we perform several validation exercises showing that our result: i) is not driven by any specific disease, although we identify larger impacts on ischemic

strokes; ii) is similar when considering only treated (ever covered) cells for identification; and iii) is robust to recent developments that allow for treatment effect heterogeneity over time or across groups (Wooldridge, 2021).

We also examine mortality effects on a subset of diseases that are considered to be “more health care–amenable” (Nolte and McKee, 2011), which previous research suggests may be more responsive to better access to medical care (Sommers et al., 2014; Sommers, 2017; Miller et al., 2021). We document that mortality falls by 7.1% for diseases that are more amenable to health care. In contrast, it only falls by 2.8% for less amenable diseases. Turning to inpatient deaths, we document that the reform decreased in-hospital mortality by 6.9%. This larger impact is consistent with the fact that individuals in the discharge records are those who sought and received medical attention. Regarding heterogeneous treatment effects, we see a larger decrease in the mortality of those below 80 years old without sizable differences between males and females. We also document that public hospitals experienced a decrease in inpatient deaths three times larger than the decrease experienced by private hospitals. Since public hospitals disproportionately serve the most disadvantaged population in the country, we interpret these findings as suggestive evidence that the reform helped to narrow socioeconomic gaps in access to healthcare.

To assess mechanisms, we study the impact of the reform on procedures. Specifically, we use hospital records and focus on inpatient surgeries. We find that surgeries increased by 15% as a consequence of the reform. Albeit sizable, this estimate implies around 2,800 extra surgeries per year, representing only a 4% of the yearly average number of inpatient surgeries in our sample. We also document that the impact on inpatient surgeries at private hospitals is small and not statistically different from zero. Again, suggesting that public hospitals were the most responsive to the reform. A sensitivity analysis reveals that the coverage of polytraumatized diseases is the main force behind the increase in surgeries, i.e., the impact of the reform on surgeries decreases from 15% to 5.6% when removing this category. All in all, we interpret these findings as evidence that the reform’s guidelines for the timely treatment of covered diseases led to increased hospital procedures.

One may worry that the estimated impact of the reform could be driven by a shift in resources from uncovered to covered diseases or by disease-specific shocks. We assess these concerns empirically using the World Health Organization mortality database and provide two pieces of evidence that strengthen the causal interpretation of our main result. First, we show both in the raw data and using a synthetic control analysis that mortality trends in non-covered diseases were not different in Chile than in other countries. Second, using an extension of our difference-in-difference approach, we show that: i) we cannot reject the null

of a zero impact of the reform on mortality from non-covered diseases (using the mortality trends of non-covered diseases in other countries as counterfactual), and ii) mortality for covered diseases does not decrease in comparable countries under a placebo treatment that uses the timing of coverage expansions in Chile for other countries. These results—which we interpret as evidence against the aforementioned concerns—are also consistent with the fact that the reform did not take funding away from non-covered diseases; instead, it created new sources of revenue by increasing the value-added tax by one percentage point, which brought in an additional 1.7% of the GDP in tax revenues per year. Using this number as a proxy for the cost of the reform together with the median estimate of the value of a statistical life in Chile (Mardones and Riquelme, 2018; Parada-Contzen, 2019), a back-of-the-envelope calculation suggests that the benefits of the reform outweighed the cost by a factor of four.

Our paper makes several contributions to the existing literature. First, it complements extensive research on the effects of health insurance on health outcomes, most of which have focused on the effects of expanding insurance based on age or socioeconomic status to previously uninsured populations. In Latin America, for instance, Arroyave et al. (2013) show that mortality disparities decreased due to doubling health insurance in Colombia, and Parker et al. (2018) suggest that the “Seguro Popular” health insurance increased utilization and diagnosis in Mexico. Regarding the U.S.’s Affordable Care Act insurance expansion, where most of the cutting-edge evidence is available, Gruber and Sommers (2019) find limited evidence of improved health outcomes, although Black et al. (2019) challenges its statistical power. Relatedly, Borgschulte and Vogler (2020) find a reduction in all-cause mortality for ages 20-64, and both Goldin et al. (2020) and Miller et al. (2021) report reductions in mortality for ages 55-64, and for causes of death likely to be influenced by access to healthcare. To the extent that the reform we study enhanced the quality of coverage, our work is also related to the experimental evidence on the impact of varying insurance generosity in the state of Oregon in the U.S. (Newhouse et al., 1993; Finkelstein et al., 2018), which shows null effects on deaths (below 65 years old) in a context with low baseline mortality, possibly due to small sample size.

In contrast to the previous studies, we use data on *all* deaths in the country and leverage quasi-experimental variation in healthcare access that is *independent* of insurance generosity to assess the impact of a program with a universal scope but aimed at prioritizing the adequate treatment of a specific set of diseases.

Second, we contribute to the literature addressing mortality inequalities by showing that the intervention had differential impacts across different groups. Building on previous studies that examine the relationship between hospital ownership and health performance in Chile

(Cid Pedraza et al., 2015; Basu et al., 2012; Alonso et al., 2019), our paper shows that inpatients at public hospitals—the largest medical bed providers serving the most disadvantaged population in the country—disproportionately benefited from this reform. In terms of demographics, we find no effects on sex-stratified samples or old age mortality compared to the groups below 80 years old. The latter is in line with the scope of the reform to prevent deaths from conditions amenable to high-quality and timely health care, usually concentrated among individuals below the ages of 75-79 (Mackenbach et al., 2017; Nolan et al., 2022).

Finally, our paper also complements previous studies of this reform. Closer to our work, Nazzari et al. (2013) conducted a survey between 2008-2009 in six public hospitals, and—focusing on acute myocardial infarction—showed the policy’s early success. Likewise, Frensch et al. (2014) used survey data to show that the reform improved access to healthcare and health status, especially among lower-income Chileans. More recently, Alonso et al. (2019) documented a higher increase in early and long-term survival, for acute myocardial infarction, in public than in private hospitals. In contrast to these papers, we use the *universe* of diseases covered in the first four waves of expansion and provide causal evidence using a quasi-experimental research design.

The remainder of the paper proceeds as follows: Section 2 describes the institutional background and the GES program. Section 3 provides details on data sources and the sample construction. In Section 4, we present: i) our empirical strategy, ii) the main result related to mortality and several robustness checks, iii) evidence on the heterogeneous effects of the reform, iv) the impact on procedures and iv) an assessment of potential confounders. We conclude with a brief discussion in Section 5.

2 Institutional Background and the GES Insurance Reform

2.1 The Chilean Health Care System

Chile has experienced rapid economic growth since the mid-1980s, with a GDP per capita of nearly \$28,500 in 2022, the highest in Latin America. The sustained economic growth has positively correlated with health outcomes over the past decades: life expectancy, avoidable mortality, chronic disease morbidity, and self-rated health is near the OECD average and above the Latin American average (OECD, 2021). However, economic growth benefits have not been accrued to everyone equally. Chile’s Gini index of 0.49 in 2017 was the second highest among OECD countries.

In the mid-80s, a two-tier health insurance system was introduced: it stipulated a mandatory 7% contribution for workers in the formal economy, who could use these contributions to obtain public or private health insurance. The *Fondo Nacional de Salud* (FONASA)'s public system is funded by taxes and mandatory contributions. It offers care mainly in public hospitals to everyone that requires it, with three levels of copay (0%, 10%, or 20%) based on the patient's income and their number of dependents.¹ Private insurance providers, *Instituciones de Salud Previsional* (ISAPREs), offer health plans for different prices and compete in a regulated market to attract those who have chosen to use their mandatory contributions in the private insurance system. Nearly 78% of the population contributes to the public system while ISAPREs only cover around 17-18% of the population. The remaining 4-5% of the population is covered by an Armed Forces insurance scheme.

While the Chilean healthcare system has extensive coverage in primary care for individuals with limited resources, this coverage can vary across different healthcare provisions partly because primary healthcare is provided through local governments. The ISAPREs, on the other hand, provide outpatient and inpatient services through their own clinics and hospitals or by contracting with other public or private facilities. Moreover, FONASA serves more people from disadvantaged backgrounds—a population with a higher risk of disease and health-related issues—while ISAPREs cover the wealthier, healthier, and younger population (Pardo, 2019).

2.2 The Explicit Health Guarantees (GES) Reform

“As part of this bill, we identify the leading causes of death: cardiovascular, cancers, and traumatism. The first group aims to decrease mortality through specific interventions for ischemic and cerebrovascular disease. Likewise, cancer mortality will be targeted through the intervention in cervix uteri, breast, vessel, and prostatic and increase palliative care coverage. Regarding traumatism, it urges stopping the increased mortality due to traffic accidents...”

Ministry of Health, Osvaldo Artaza addressing Chilean congress in 2004.

In 2001, the Chilean government conceived the GES program as a major reform to the Chilean health system to achieve effective Universal Health Coverage.² The country made

¹It is worth mentioning that *within* FONASA, there is an option that facilitates access to care at private providers known as the Free Choice Modality (*Modalidad de Libre Elección*). This option allows users in the high-income segment to use private providers while incurring an increased copayment.

²For details on Universal Health Coverage, see (The Lancet, 2019).

a novel effort to guarantee access, provide timely care administration, improve quality, and secure financial coverage for specific health-related problems with high mortality, morbidity, and financial impact (Vargas and Poblete, 2008). These conditions encompassed heart attacks, ischemic stroke, hypertension, diabetes, pneumonia, specific cancers, and traumatism, among others. Although these health conditions were previously covered by public and private providers under the government's universal health care policies, timely access, quality, and financial protection were limited (Paraje and Infante, 2015). Indeed, the presence of waiting lists in the public sector presented a notable obstacle to obtaining timely care, especially in the case of highly specialized treatments and complex surgeries (Erazo, 2011), and high medical expenditures were identified as the second most common cause of income shocks experienced by households (Neilson et al., 2008).

The GES reform ensured, for the first time, a standardized benefit plan that granted equal entitlement to beneficiaries of public and private insurers, guaranteeing timely access to high-quality care for top-priority conditions with financial protection (Erazo, 2011). It ensures financial security through limits to contributions, payments, and co-payments. Depending on the health-related problem, people may also have access to free prescriptions. This new regulation also aimed to address insurers' previous tendency to exclude services and reduce financial protection. To explore this critical dimension of the reform, in Appendix C, we use longitudinal survey data to study the correlation between GES coverage and the number of medical visits and out-of-pocket health expenditures. We find that—among respondents who report ever being diagnosed with a health condition—those whose health condition was covered by the GES program were 46% more likely to report a medical visit (and when reporting, reported 40% more visits) and 26% less likely to report out-of-pocket medical expenditures (and when reporting, declared 49% lower healthcare spending). These effects remain sizable, albeit smaller, and statistically significant if we include person-fixed effects, thus leveraging within-person variation in the timing of GES coverage (See Appendix C for details).

The implementation of disease-specific clinical guidelines was a key aspect of the program.³ The guidelines defined a timeline for the diagnosis, treatment, and follow-up to achieve timely care administration with a maximum out-of-pocket expense cap and a maximum waiting time, after which it is possible to seek care through private providers (Bitran, 2013). To ensure quality, the GES program mandates using registered and certified health providers. In most cases, once a public or private health provider verifies the diagnosis, pa-

³For the interested reader, all clinical guidelines are available in this [link](#) or directly accessing: <https://diprece.minsal.cl/le-informamos/auge/acceso-guias-clinicas/guias-clinicas-auge/>.

tients are assigned to treatment in a specific network and cannot choose where to get care; otherwise, they lose the benefit. To illustrate the changes introduced by the reform, we can consider the case of a time-dependent disease such as Acute Myocardial Infarction (AMI); for which there were no standardized procedures before the GES program. After the reform started, the GES program covers and mandates i) for diagnosis: an electrocardiogram and a specific blood test to estimate cell death; ii) for treatment: an angioplasty in less than 90-120 minutes at high-complexity facilities or a thrombolysis within the first 30 minutes at low-complex facilities. Although timely diagnoses and treatment are essential for the prognosis and mortality rate of this pathology, procedures varied across providers before the reform, particularly between metropolitan and non-metropolitan areas without high-complexity hospitals.

When initially conceived, the reform intended to cover 56 health-related problems simultaneously. However, coverage was gradually rolled out to pilot performance and to provide the system with enough resources. Identifying requirements for human resources, equipment, technology, and infrastructure considering the specific needs associated with each health condition was critical (Paraje and Infante, 2015). The intervention started with a small pilot in August 2002, covering terminal chronic kidney diseases, all childhood cancers, and congenital heart disease. Then, in 2003, cervicouterine and terminal cancers (palliative care) were added. Finally, in 2004, the reform started as a formal pilot for publicly insured patients seeking care in public hospitals, who represented 73% of the population (MINSAL, 2004). This is considered the initial expansion, covering 17 new priority conditions, including high-prevalence diseases amenable to mortality-averting healthcare treatment, such as heart attacks, hypertension, and diabetes. Subsequent developments in 2005, 2006, 2007, 2010, 2013, and 2019 brought the total to eighty-five covered conditions of varying prevalence and amenability to care. Relevant to our empirical approach is the fact that coverage also targeted specific age groups for some diseases. For instance, bronchial asthma was covered by the 2006 expansion for people below 15 years old, but in 2010 coverage expanded for those above 15 years old. Another example is cholecystectomy, a standard treatment of symptomatic gallstones and other gallbladder conditions, which is covered only for people between 15-39 years old. Detailed tables with each covered health-related problem and age group can be found in Appendix Tables A.1 through A.4.

Although novel, the measures implemented by the GES reform resemble practices embedded in other countries' health systems. The Norwegian system, for instance, establishes "patient rights" to access quality healthcare and stipulates minimum waiting times for complex treatments, such as those requiring surgeries. Likewise, in Sweden, if the guaranteed time

for treatment is exceeded, treatment is covered in private institutions or abroad. Additionally, financial protection establishes a maximum annual amount for outpatient co-payments. Both the UK and The Netherlands also explored plans to combine a focus on cost-effectiveness with the use of clinical guidelines developed by expert boards to reach quality at an affordable cost (Casparie, 1991). Outside of Europe, in the '90s the State of Oregon in the U.S. implemented The Oregon Health Plan, an expansion of insurance coverage based on a prioritized list of health services, along with their treatments, ranked according to their clinical cost-effectiveness.⁴

3 Data and Sample Construction

3.1 Data Sources

The primary mortality dataset is an individual-level death registry coming from the death certificates. This dataset provides us with each individual's cause of death, birth year, sex, and place of residence. It comprises every death in the country between 1997 and 2017, almost 2 million records. The secondary data contains patient-level records of discharges from the entire health system between 2001 and 2017. These correspond to almost 28 million records of patients who stayed at least one night in a healthcare facility. It includes the patient's discharge diagnosis and demographics such as birth year, sex, and place of residence. Furthermore, it includes information on surgeries performed, whether the patient was dead or alive when discharged, the type of insurance coverage, and the type of hospital where they received treatment and/or passed away (public or private).

Both datasets result from a joint effort between the National Statistics Office, the Vital Records Office, and the Statistics Department of the Ministry of Health. The primary goal of these agencies is to classify each cause of death and patient discharge diagnosis according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10). Key to our empirical strategy is the fact that the reform defined coverage and clinical guidelines based exclusively on the patient's diagnosis (ICD-10 code) and age group. The list of covered diseases by ICD-10 and age group is publicly available on the Ministry of Health [webpage](#). In terms of data quality, Chile's vital statistics rank among the best in the world (Mikkelsen et al., 2015). As shown in Figure A.1, the country has an established protocol to record deaths (Government of Chile, 2016); and neither patients nor

⁴In this case, based on the state budget and the estimated benefits and costs, the state drew a line, and included those services and treatments that were above it (Dixon and Welch, 1991).

health providers have incentives to influence the diagnoses for billing purposes. On the one hand, all patients in the public system must follow a strict referral system and cannot choose their hospitals or physicians. On the other hand, the diagnoses are recorded directly by the lead physician, who must follow the nationwide mandatory program that aims to characterize the morbidity profile of patients for policy purposes ([Government of Chile, 2010](#)). Moreover, to access the coverage provided by the GES program, the medical team must perform specific exams and provide objective evidence that backs up their diagnoses.

Finally, to address concerns related to disease-specific shocks or shifts in health resources from non-covered to covered diseases, we use the World Health Organization (WHO) mortality dataset.⁵ Specifically, we use the death counts by ICD-10 and age categories from countries in the Central and South American region that are classified as countries with high data usability, according to the WHO ([WHO, 2020](#)). These countries are Belize, Mexico, Venezuela, Paraguay, Brazil, Costa Rica, Nicaragua, Panama, and Colombia.

3.2 Sample Construction and Descriptive Statistics

To construct our analysis sample, we first identify all diseases that result in deaths. We then combine individual deaths and discharge records to construct cells with the counts of deaths, in-hospital deaths, and surgeries by the ICD-10 disease codes and 22 age groups defined as 19 five-year age groups and three ad-hoc groups (newborns, ages 1 to 4, and open-ended interval for deaths above 100). We classify each resulting cell as covered or non-covered using the comprehensive list of ICD-10 codes and ages covered by each of the GES expansions between 2004 and 2007. We also identify cells from conditions that are amenable to health care following [Nolte and McKee \(2011\)](#) and [Sommers et al. \(2014\)](#). See Appendix Table [A.5](#) for a detailed list of the ICD-10 codes included.

Our sample excludes diseases considered in the pilot program that happened between 2002 and 2003 because: i) it is not clear how these conditions were chosen, and ii) we only have discharge records starting in 2001.⁶ We also decided not to consider diseases included in the second wave of expansions (in the years 2010, 2013, and 2019) in our study. The main reason for this decision is that the 2010 and 2013 groups of covered diseases were piloted before the program formally expanded, which could introduce bias to our estimates. Likewise, we do not consider the 2019 expansion because it included four cancers that were already covered during the 2002-2003 pilot under “cancer palliative care”.⁷

⁵These data is publicly available in the [WHO webpage](#).

⁶This group represents 15.8% of all deaths in the period we study, and 69% of these were terminal cancers.

⁷The 2019 expansion also covered Alzheimer’s and other dementia. We decided not to include Alzheimer’s

As mentioned in subsection 2.2, for some diseases, later expansions only increased age-group coverage. For example, in our sample, we only study age groups below 15 for bronchial asthma because coverage was expanded to include those above 15 in the 2010 expansion, which is not part of the set of expansions that we study. For the same reason, there are diseases in both covered and uncovered groups, i.e., because their coverage was only for a specific age group. For the exact number of diseases and disease-age cells covered, see Appendix Table A.6. Moreover, among diagnoses covered within our time frame, 16 did not have deaths during the study period. These diseases, excluded from our analysis, correspond to scoliosis, cataracts, refractive impairment, strabismus, oral health for children, diabetic retinopathy, detached retina, depression, orthotics for older adults (canes, wheelchairs, others), dental emergencies, tooth loss in older adults, traumatic brain injury, eye trauma, delivery care with analgesia, major burns, hypoacusis. Thus, we end up with a yearly panel with counts by age group and ICD-10 codes for 35 health-related problems covered by the reform during the 2004, 2005, 2006, and 2007 expansions.

Almost 60% of deaths in our sample are concentrated among diseases of the circulatory, respiratory, and digestive systems. Neoplasms and injuries account for an additional 20% (for details, see Table A.7). Table A.8 reinforces the targeted nature of the reform by showing that all expansions combined targeted almost 50% of deaths in the period of our study in an evenly distributed fashion (between 10-15% in each expansion). Finally, Table A.9 presents descriptive statistics regarding the age structure of our sample. We see that almost 75% of deaths occurred between the ages of 50 and 89. We also see the usual pattern of increasing deaths with age, peaking in the 80-84 age group and then decreasing. This table also shows that the reform covers around 50% of deaths within each age group. For the 2007 distribution, there is an interesting pattern. The number of deaths decreased with age, which aligns with the fact that most of these deaths are related to polytraumatized health problems.

Regarding the WHO Mortality dataset, we construct a panel of cells using the same procedure described above and classify them as covered and non-covered using the ICD-10, age categories, and the timing of the Chilean GES reform. A difference between our primary dataset and the WHO database is that the latter has an open-ended age interval of 95 years and above, while ours has an open-ended interval of 100 years and above. Moreover, the WHO database classifies deaths under chapter XIX (that ranges from S00 to T98), titled “Injury, poisoning and certain other consequences of external causes” based on the *underlying* cause of death. In contrast, we considered them as the leading cause of death. As shown in

and other dementia in our analysis because the classification of deaths as a consequence of Alzheimer’s has been unstable over time (e.g., some deaths previously recorded as epilepsy are now recorded as Alzheimer’s). Nonetheless, our results are robust to including these diseases as controls.

the next section, we find quantitatively and qualitatively similar results for Chile when using the WHO data.

4 The Impact of the GES Reform

In this section, we begin presenting our empirical strategy and the main results on the impact of the reform on mortality (alongside several robustness checks). We also show the heterogeneous effects of the reform and its impact on procedures, using inpatient surgeries as a proxy. We end this section with an assessment of potential confounders.

4.1 Empirical Strategy

The phased implementation of the reform coverage allows us to implement a staggered difference-in-differences research design. In particular, we can use the timing of coverage among different disease-age cells to study changes in cell-level outcomes (e.g., deaths) before and after coverage. Because we only observe deaths but not how many individuals suffered from each disease, we cannot construct disease-specific death rates. Thus, the outcomes of interest will be yearly counts within a disease-age cell (e.g., the number of deaths or inpatient surgeries associated with polytrauma among people between 35 and 39 years old in a given year); and we will fit Poisson models for counts using a log link, with a general specification given by:

$$y_{dt} = \exp(\alpha_d + \gamma_t + \beta GES_{dt} + \epsilon_{dt}), \quad (1)$$

where y_{dt} is the count of our outcome of interest for a cell d (a disease-age combination) in period t . GES_{dt} is an indicator that equals one from the first time a disease-age cell is covered and onward, i.e., the treatment is an absorbing state. α_d represents cells' fixed effects that control for unobservables specific to the disease-age group, and γ_t are time-fixed effects that account for year-specific shocks common across diseases. Finally, ϵ_{dt} is an error term clustered at the level of treatment: disease-age cell. In this model, identification of the *causal* effect of the GES reform is predicated upon the assumption that—conditional on time-invariant disease-age cell indicators and year aggregate shocks—there are no unobserved factors that correlated with both the timing of coverage and other determinants of health outcomes.

Our parameter of interest is the rate ratio (RR) identified through the Poisson model. For

two time periods case, the RR is defined as:

$$RR = \exp(\beta) = \frac{\frac{E[Y_{d2}|GES=1]}{E[Y_{d1}|GES=1]}}{\frac{E[Y_{d2}|GES=0]}{E[Y_{d1}|GES=0]}}, \quad (2)$$

where Y_{dt} is the count of our outcome of interest for diseases-age cell d in period t , and GES equals one when a cell is covered. A rate ratio, sometimes called an incidence density ratio or incidence rate ratio is the relative difference measure used to compare the incidence rates of events occurring at any given point in time (Dicker et al., 2006). Therefore, the interpretation of the value of a rate ratio is similar to that of the risk ratio. That is, a rate ratio of 1 indicates equal rates in the two groups, and a rate ratio greater than 1 indicates an increased risk for the treated group ($GES = 1$). In contrast, a rate ratio less than 1 indicates a decreased risk for the treated group ($GES = 1$). To ease the exposition, we present our results as percent changes by subtracting one from the RR, i.e., $\exp(\beta) - 1$. Thus, if the GES reform led to a relative decrease in the number of deaths among covered diseases, we would expect our coefficient to be negative.

In our setting, the testable identification assumption, commonly known as “parallel trends”, requires that the death ratios between the group of diseases (covered and non-covered) would have been constant over time in the absence of the reform. For this reason, this assumption is also referred to as “parallel relative trends”. To assess the plausibility of this parallel (relative) trends assumption, we examine the dynamic effects of GES using event studies around the time when new diseases become covered. To be consistent across death and inpatient records, we use a 3-year moving window around each expansion. Nonetheless, we also present the event study for our main outcome (all deaths) using a 7-year moving window.⁸

To estimate the dynamic version of our difference-in-differences specification, we use a leads-and-lags model in event time, with the first expansion year set to zero. Specifically, we estimate the following equation:

$$y_{dt} = \exp\left(\alpha_d + \gamma_t + \sum_{k=\underline{C}}^{-2} \beta_k D_{dt}^k + \sum_{k=0}^{\bar{C}} \beta_k D_{dt}^k + \epsilon_{dt}\right), \quad (3)$$

where $D_{dt}^k = 1[t = GES_d + k]$, and GES_d is the timing of inclusion of disease-age group d . In other words, D_{dt}^k is a dummy variable indicating that disease-age cell d was included in the GES program k periods ago (or will be included k periods ahead, for negative values

⁸A seven-year window is the largest window that allows us to work with a balanced panel of events, i.e., $t = -7$ in 1997 for the first wave of coverage in 2004, and $t = 6$ in 2014 for the last wave of coverage in 2007.

of k). We normalize the coefficients such that $\beta_{k=-1} = 0$, i.e, treatment is re-coded in event time relative to the year before each disease-age group was included in a GES expansion. Therefore, the β_k coefficients can be interpreted as the effect of GES on the outcome y_{dt} for each k period relative to the year before the inclusion of d in the GES program.

4.2 Did the Reform Reduce Mortality?

We begin by exploring the mortality impact of the reform using raw data. In Figure 1, we plot the change in the number of deaths in covered diseases against non-covered diseases for each expansion. Panel (a) shows that the change in deaths covered by the 2004 expansion decreased compared to the non-covered group. Panel (b) shows that deaths of diseases covered in 2005 also decreased proportionally more than deaths of non-covered diseases a year after the expansion, although the difference between covered and non-covered is smaller than in panel (a). Panel (c) shows the evolution of deaths for diseases whose coverage was included in 2006. In this case, there is also a decline compared with the non-covered group of diseases. Finally, panel (d) shows the differential trends between diseases included in the 2007 expansion and those non-covered. Again, all deaths increased, but those covered by the 2007 expansion increased far less. Importantly, the overall increase in deaths shown in Figure 1 is mainly driven by an aging population.⁹

Even though previous evidence is purely descriptive, it suggests that reform coverage led to a decrease in mortality. To formally study this hypothesis—and to quantify the impact of the reform—we now present the results of our staggered difference-in-differences research design. Table 1 presents the estimates obtained from model (1). Our main result is presented in Column (1) and considers the count of all deaths as the dependent variable. Consistent with the preliminary evidence, we find a statistically significant impact of the reform on mortality: the average risk of dying from diseases going from uncovered to covered decreases by 4.4% after the reform.¹⁰ This effect is a weighted average across all disease-age cells and expansions, which allows us to compute the number of deaths averted due to the reform. In our estimation sample, the covered group had 38,129 deaths in the pre-expansion period. Therefore, there were 1,678 deaths averted once they went from uncovered to covered.

⁹Appendix Figure A.2 shows standardized cause-specific death rates accounting for population growth and population aging by weighting yearly death rates with the age distribution in 2001. It shows that adjusted death rates are actually *decreasing* throughout the analysis window. For the interested reader, Appendix Figure A.3 presents population pyramids showing how the age distribution has changed in Chile during the last 3 decades.

¹⁰We obtain similar results if we estimate a negative binomial regression that allows for overdispersion or if we use linear regressions either with the log of deaths+1 or the inverse hyperbolic sine of deaths as ad-hoc transformations to deal with the zero count cells. Appendix Table A.10 present these results.

To assess the dynamics of the impact on mortality, Figure 2, panel (a), presents the event study estimates obtained from model (3) using the count of deaths as the dependent variable.¹¹ The horizontal axis shows the years relative to the coverage expansion, with event time zero denoting the first year of expansion. We omit event time -1 so that all estimates are relative to the year before the expansion. Point estimates of leads and lags are plotted along with their 95% confidence intervals. The figure shows that pre-period estimates are not statistically different from zero, a result in line with our parallel relative trends assumption. Moreover, the figure shows that the number of deaths in treated disease-age cells decreased after their coverage and remained stable at around -4% over time.

As mentioned in section 3, death records using the ICD-10 classification have been available since 1997. Thus, we can add more pre-periods to better assess the parallel trends assumption for our main outcome: deaths. Figure 2, panel (b), presents the event study estimates obtained from model (3) when considering data from all years $\in \{1997, 2014\}$ and imposing the following endpoint restrictions: $\beta_k = \bar{\beta}$ if $k \geq 7$ and $\beta_k = \underline{\beta}$ if $k \leq -7$, which state that any dynamics wear off after seven years.¹² Reassuringly, the dynamics presented in panel (b) resemble those of panel (a), with pre-period estimates not statistically different from zero and a stable decrease in deaths after reform coverage. We complement previous evidence on the validity of our research design by showing pre-treatment characteristics (coming from the death records) for covered and non-covered cells. As shown in Appendix Table A.11, there is balance along an array of cell characteristics, including the type of insurance, highest educational level attained, gender, marital status, and geographical location.

Recent literature on two-way fixed effects estimators has shown that estimates from linear models can differ from the group’s average treatment on the treated (ATT) in the presence of treatment effect heterogeneity (De Chaisemartin and d’Haultfoeuille, 2020; Callaway and Sant’Anna, 2021; Sun and Abraham, 2021). To address this concern, we implement a recent method that recovers the group’s ATT in non-linear settings like ours while allowing treatment effects to be heterogeneous over time or across groups (Wooldridge, 2021, 2022; Rios-Avila, 2022). Our estimated ATTs imply a decrease in deaths of 6.1% (with a standard error of 1.6%) when using *never covered* cells as controls and a decrease in deaths of 4.6% (with a standard error of 1.8%) when using *not yet covered* cells as controls. These estimates are both statistically significant and align with the ones presented in Table 1.¹³ In the same

¹¹ Appendix Figure A.4 presents the corresponding event study for Poisson and Negative Binomial models.

¹² For another example of such endpoint restrictions, see McCrary (2007) and Kline (2011).

¹³ Intuitively, this approach assesses the impact of the GES expansions jointly while allowing each expansion to have its own dynamic. Thus, in Appendix Figure A.5, we also present the event studies obtained from estimating a Poisson regression saturated with the interaction of all treatment cohorts (GES expansions) and event time dummies. The regression includes cell and year-fixed effects. These event studies are consistent with

vein of the previous exercise, column (2) of Table 1 presents the results obtained from estimating equation (1) in a sample of *ever covered* cells. In this case—where we only leverage variation in the timing of adoption among covered diseases for identification—we also find that expansions led to a 4% decrease in mortality.¹⁴

In light of recent research suggesting that some diseases may be more responsive to access to medical care than others (Sommers et al., 2014; Borgschulte and Vogler, 2020; Miller et al., 2021), we study the impact of the reform on two subsets of diseases: those considered to be more “health care–amenable” and those considered to be less “health care–amenable”. For this analysis, we use the classification described in section 3.2.¹⁵ Columns (3) and (4) of Table 1 shows the estimates obtained from estimating model (1) on “More amenable” and “Less amenable” diseases; and Figure 3 presents the corresponding event studies. For both sets of diseases, we find that the reform had a negative and statistically significant effect. Nonetheless, the magnitudes of these effects are substantially different, with the effect on more amenable diseases more than doubling the effect on the rest of the diseases. According to our estimates, deaths from diseases more amenable to health care decreased by 7.1% due to the reform. This is a large effect on a relatively smaller set of deaths, suggesting that a significant part of the effect on mortality is driven by the targeting of diseases that are more amenable to health care. In Appendix Table A.15, we perform a robustness check and repeat this analysis under alternative classifications of amenable deaths, including Tobias and Yeh (2009), Nolte and McKee (2003), and the one used by the European Union. We find similar results in all these cases.

Finally, to complement our previous results, we also study the impact of the reform on inpatient deaths. In column (5) of Table 1, we present the estimates obtained from estimating model (1) using the count of in-hospital deaths as the dependent variable. We find that in-hospital mortality decreased by 6.9% as a consequence of the reform. This effect, larger than the impact on the population as a whole, is consistent with the fact that in-hospital deaths come from a sample of patients for whom we know medical care was provided and who spent at least one night at a healthcare facility, i.e., they show up in the hospital’s discharge records. Panel (c) of Figure 2 shows the event study for in-hospital deaths. Similar to the dynamics observed for other counts of deaths, differences between covered and non-covered diseases were almost nonexistent before the reform. However, right after expansion coverage, the

our main findings across all expansions.

¹⁴For the interested reader, in Appendix Table A.12 and Figure A.6 we also present estimates of the impact of the reform when considering different expansions of the program (i.e., different sets of diseases covered at different points in time) and using only never-covered cells as controls.

¹⁵Our classification encompasses both the work by Nolte and McKee (2011) and by Sommers et al. (2014). See Appendix Table A.5 for details.

number of inpatients deaths in covered diseases decreased and remained permanently lower.

4.3 Heterogeneous Impacts of the Reform

In this subsection, we replicate our analysis in different sub-samples to study the heterogeneous effects of the reform along the socioeconomic, demographic, and geographical dimensions. We also perform a sensitivity analysis to assess whether a particular disease (or group of diseases) is driving the decrease in mortality.

We begin estimating the model given by equation (1) in different sex and age groups samples. This analysis is motivated by the fact that some diseases expanded only for specific sex and age groups. Columns (1) to (5) of Table 2 present our results. Even though the reform targets sex-specific diseases, we find no significant differences in mortality for males and females. In contrast, we do find important differences between age groups. Notably, the decrease in deaths between ages 0 and 49 is almost four times larger than the decrease in deaths among those above 80. The absence of an effect on old age mortality may be associated with the focus of the reform on deaths amenable to high-quality and timely health care, which are usually found in patients below the age of 75-79 (Mackenbach et al., 2017; Nolan et al., 2022).¹⁶ It can also be related to the fact that co-morbidity increases with older age; hence, assigning a single underlying cause of death becomes more uncertain at older ages, making the classification noisier for these groups of deaths (Weber and Clerc, 2017).

We now turn to explore socioeconomic disparities. In Chile, public hospitals are more crowded and have longer wait times. As of 2016, only 24% of the 348 hospitals in the country were private, but 55% of doctors worked in the private sector (Clinicas de Chile, 2016; Gonzalez et al., 2022). Additionally, previous studies found that patients at public hospitals show a higher risk of in-hospital death (Cid Pedraza et al., 2015). In this context: did patients seeking care at public hospitals benefit more from this reform? To answer this question, we estimate the model given by equation (1) again, but now using discharge records and stratifying inpatients by type of healthcare provider. Columns (6) to (8) of Table 2 present our results. We find that the reform reduced mortality in public hospitals by 7.3%, a large and statistically significant effect.¹⁷ In private hospitals, however, the reform reduced mortality only by 2.5%, a smaller and not statistically significant effect. Insofar as public hospitals are

¹⁶In our sample, 23% of deaths more amenable to healthcare are below 50 years old, and 77% are among those between 50 and 79 years old. None of the deaths after 80 years old are classified as deaths more amenable to health care

¹⁷Appendix Table A.13 shows that this result is robust to the removal of diseases included in the pilot expansion of 2004, which exclusively targeted patients with public insurance seeking care at public hospitals.

the most prominent medical bed providers and serve the most disadvantaged population,¹⁸ we interpret this result as evidence that the reform contributed to closing socioeconomic gaps in healthcare.

Motivated by the literature on geographical disparities in health (Murray et al., 2006; Bilal et al., 2019; Mena et al., 2021), we also study heterogeneous effects of the reform by the geographic location (residence) of the deceased. Appendix Table A.14 presents the results obtained from estimating the model given by equation (1) in six different samples defined by the major geographical areas of Chile. Our estimates show that the reform decreased mortality by more than 5% in all but the relatively more affluent northern and metropolitan areas. In summary, our heterogeneity analysis shows that the reform: i) had similar effects for men and women but a more considerable impact on the mortality of people below 80 years old, an age group where deaths amenable to high-quality and timely health care are concentrated; ii) had a significant effect on public but not in private hospitals, suggesting it helped to reduce socioeconomic disparities; and iii) had a weaker impact on richer geographical areas, suggesting that the reform also helped to narrow geographic disparities.

Finally, we study whether a particular disease or group of diseases drives our results. For this purpose, we estimate our main difference-in-differences model, given by equation (1), but removing one covered cell (i.e., a disease-age category) from our sample at a time. Figure 4 plots the point estimates and 95% confidence intervals obtained from this exercise. In all regressions, we find negative and statistically significant impacts of the reform on mortality. Moreover, most point estimates are around the average effect of a 4.4% decrease in mortality. A few disease-age categories stand out as triggers of changes in our main estimate. Among them, we see arterial hypertension, disorders of the heart conduction systems, and polytraumas (with and without medullary lesions). On the one hand, the removal of arterial hypertension and disorders of the heart conduction systems leads to more substantial impacts of the reform (~ 5% instead of a 4.4% decrease in mortality). On the other hand, removing polytraumas leads to weaker impacts of the reform (~ 3.8% instead of 4.4% decrease in mortality).

The most salient change in the estimated impact of the reform on mortality happens when we remove ischemic strokes from the estimation sample. In this case, the estimated decrease in deaths shrinks from 4.4% to 3.1%. Ischemic strokes were an important contributor to mortality in Chile. Indeed, among diseases covered during the 2006 expansion, ischemic strokes are the largest category in terms of deaths, i.e., they represent 30.6% of all deaths.¹⁹

¹⁸Based on our discharge records, 96% of patients at public hospitals have public insurance.

¹⁹See Appendix Table A.3 for details.

Moreover, the reform significantly modified procedures for the diagnoses, treatment, and follow-ups associated with this disease. Before the reform, the diagnosis was made through computed tomography (CT) scans of the brain; after GES, in addition to the CT scan, an angiography of the brain and neck is recommended. Regarding treatment, for those with an intracranial large vessel occlusion, thrombolysis was the standard procedure before the reform; after it, thrombectomies are performed by neurologists. In the case of a stroke with a foramen ovale, it also must be closed (in addition to the antithrombotic treatment). In terms of medication, the reform's guidelines suggest using oral anticoagulants instead of the vitamin K antagonists that were previously used. Finally, regarding the follow-ups, the guidelines suggest initiating motor therapy within the first 24 hours and a high volume of rehabilitation sessions; before the GES program, there were no clear timelines nor guarantees for when to start rehabilitation.²⁰

4.4 Impact on Inpatient Surgeries

Identifying the underlying mechanisms behind the fall in mortality is challenging. Nonetheless, we can leverage hospital records and look at inpatient surgeries as a proxy for procedures.²¹ In Table 3, we present the results obtained after estimating the Poisson model given by equation (1) but using the count of inpatient surgeries as the dependent variable. Column (1) shows that surgeries increased by 15% as a consequence of the reform. Albeit sizable (as a percentage increase among covered diseases), the surge in covered surgeries implies only a 4% increase in overall surgeries.²² Regarding heterogeneous effects, columns (2) to (5) of Table 3 show that the impact of the reform on inpatient surgeries was larger for males than for females (20% vs. 13%) and was entirely driven by public hospitals, i.e., the estimated impact of the reform on surgeries at private hospitals is indistinguishable from zero. Reassuringly, the corresponding event studies presented in Appendix Figure A.7 show no evidence of pre-trends and indicate that surgeries increased steadily after the reform.

To study whether a particular disease or set of diseases is driving the increase in surgeries, we repeat the sensitivity analysis in which we estimate our difference-in-differences model but remove one covered cell from the sample at a time. Figure A.8 plots the point

²⁰For more details, see the corresponding clinical guideline available in this [link](https://diprece.minsal.cl/garantias-explicitas-en-salud-auge-o-ges/guias-de-practica-clinica/ataque-cerebrovascular-isquemico-en-personas-de-15-anos-y-mas/recomendaciones-2/) or directly accessing: <https://diprece.minsal.cl/garantias-explicitas-en-salud-auge-o-ges/guias-de-practica-clinica/ataque-cerebrovascular-isquemico-en-personas-de-15-anos-y-mas/recomendaciones-2/>.

²¹To the extent that the treatment of several diseases covered by the reform does not involve overnight surgery, our proxy will understate the impact of the reform on procedures.

²²The 15% increase implies around 2,800 extra inpatient surgeries per year, and the average number of inpatient surgeries per year in the country is around 70,000.

estimates and 95% confidence intervals obtained from this exercise. We see that most point estimates are around the average effect of a 15% increase in inpatient surgeries, except for the one obtained after the removal of the polytraumatized category. As shown by columns (6) and (7) of Table 3, the impact of the reform on surgeries goes from 15% (p-val < 0.01) to 5.6% (p-val < 0.05) after removing this category. This result is consistent with the aim of the reform of guaranteeing timely access to care to anyone who presents traumatic injuries affecting at least two systems (of which the failure of one can be life-threatening). Before the reform, procedures to treat polytraumas were not uniform across providers; after it, clinical guidelines address the management of polytraumatized patients from the moment of rescue at the accident site until the completion of treatment in the intensive care unit, emphasizing damage control and the repair of injuries. This finding is also consistent with Ramos et al. (2021), whose study of a landmark public hospital in Chile shows that more than 50% of polytraumatized patients receive surgery as part of their treatment.

4.5 Assessment of Potential Confounders

Before concluding, we discuss whether diseases-specific shocks or a resource shift from non-covered to covered diseases could confound our results.

If the reform led to a reallocation of resources from uncovered to covered diseases, then it might have inadvertently caused a worsening in the provision of healthcare for non-covered diseases, thereby qualifying the interpretation of our findings. In light of this, it is worth noticing that—*de jure*—the reform did not remove funding from non-covered diseases. Instead, the government passed a tax reform to fund the GES program (bill No. 19,888, enacted in August of 2003), which increased the value-added tax by one percentage point and brought in an additional 1.7% of the GDP in tax revenues one year after its implementation.²³ Nevertheless, the true impact of the reform on the mortality from diseases not covered is ultimately an empirical issue. To address this, we use the World Health Organization’s mortality database, which allows us to compare the evolution of mortality in Chile vis-a-vis in other countries of the Central and South American region.²⁴

For each country, we construct a panel of disease-age group cells resembling the ones used in our main analysis and classify them as covered or non-covered using the ICD-10

²³Between 2000 and 2010, the proportion of the GDP allocated to healthcare spending grew from 2.8% to 3.5% (Government of Chile, 2021).

²⁴We only consider countries with high data usability as defined by WHO (2020). These countries are Belize, Mexico, Venezuela, Paraguay, Brazil, Costa Rica, Nicaragua, Panama, Colombia, and Chile. All data is publicly available in the WHO webpage (<https://www.who.int/data/data-collection-tools/who-mortality-database>).

codes, age categories, and the timing of the Chilean GES reform. We begin by focusing on the mortality trends in non-covered diseases. Figure 5, panel (a), shows the time series of the yearly percentage change in deaths from non-covered diseases in Chile and other countries. Encouragingly, we observe that the trend of deaths from non-covered diseases in Chile is similar to the trends for other countries, fluctuating closely around zero over our sample period. To enhance this descriptive analysis, we construct a synthetic control for Chile using lags of the logarithm of deaths, the logarithm of cumulative deaths, and the growth of deaths before 2004, the first year of the GES reform. These variables are employed to calculate the weights given to each country following [Abadie et al. \(2010, 2015\)](#). Panel (b) of Figure 5 presents this result. We observe that the logarithm of deaths (from non-covered diseases) in Chile matches the evolution of deaths (from non-covered diseases) in the synthetic control closely up to 2004, with no clear signs of divergence afterward, lending support to our previous finding of no abnormal growth in mortality among non-covered diseases in Chile after the reform.

To further assess if the provision of healthcare for non-covered diseases got worse and to address the concerns related to disease-specific shocks that could confound our results, we estimate alternative difference-in-differences models using different samples of the WHO mortality database. We present these results in Table 4, but before discussing them—and as an important data quality check—we replicate our main result presented in column (1) of Table 1 now using the WHO data for Chile. In this case, considering covered and non-covered diseases, we estimate a similar impact of the reform: a 3.6% decrease in deaths. The difference between this and our main estimate of -4.4% might stem from the fact that the WHO has a different age grid for the elderly and classifies deaths under chapter XIX differently than the Statistics Department of the Chilean Ministry of Health.²⁵ In column (2), we also focus on Chile but now considering exclusively ever-covered cells (i.e., removing non-covered cells from the control group). The magnitude of the treatment effect in this case, when we leverage only the timing of coverage among covered diseases, is -3.9%, similar to the -4.0% previously reported in column (2) of Table 1.

To address concerns about disease-specific shocks to mortality that could have coincided with the timing of the GES reform, we performed a placebo check using other countries. Specifically, we considered only the disease-age groups that were ever covered, and for

²⁵The difference between the Chilean-source data and the WHO database is that the latter has an open-ended age interval of 95 years and above while the former has an open-ended interval of 100 years and above. Moreover, the WHO database classifies deaths under chapter XIX (that range from S00 to T98), titled “Injury, poisoning and certain other consequences of external causes”, based on the *underlying* cause of death. In contrast, we considered them as the leading cause of death.

them, we estimated a placebo difference-in-differences that uses the timing of coverage of the Chilean reform. In this case, and to be consistent across specifications, we interact cell and year dummies with country-fixed effects. As shown by column (3) of Table 4, we cannot reject the null of a zero impact of the timing of coverage in Chile on other countries' mortality. In column (4), we extend the previous specification now considering all countries and adding an interaction between a binary indicator for "After GES Expansion" and a binary indicator for "Chile". Insofar as we use the evolution of *covered* diseases in other countries as a counterfactual for Chile, this specification allows us to isolate the impact of the reform from i) idiosyncratic trends in non-covered diseases and ii) shocks that are specific to covered diseases (and common across countries). Reassuringly and consistently with columns (2) and (3), we find that the negative impact of the reform on deaths is significant in Chile but not in other countries.

Finally, in column (5), we compare the evolution of mortality in non-covered diseases in Chile to that of other countries. For this, we interact an indicator variable equal to one for "Chile" with an indicator variable equal to one for the period after 2004 (the year when the reform started). In addition to year and cell fixed effects, this specification also includes an indicator variable equal to one for Chile. In line with our previous results (Figure 5), we cannot reject the null of a zero impact of the reform on non-covered diseases.²⁶ In summary, our analysis using the WHO Mortality Database revealed: i) no significant changes in mortality from covered diseases in other countries (that coincide with the timing of the Chilean reform), ii) no indication of an abnormal increase in mortality from non-covered diseases in Chile after the reform (relative to comparable countries).

5 Discussion

As the international community prioritizes cost-effective policy interventions to achieve universal health coverage (The Lancet, 2019),²⁷ the need for rigorous evidence on the impact of health reforms has increased. In this article, we studied the impact of a large health reform that standardized procedures across health providers to guarantee medical treatment for sick patients independent of their insurance or income and based solely on their diagnoses and

²⁶The estimated impact is not negligible (2.3%) but, despite a large number of observations (> 1 million), it is very noisy. In unreported results, we estimate this regression several times to compare deaths in Chile to deaths in other countries, one at a time. For 5 (out of 9) countries, we find that there was a *decrease* in deaths in non-covered diseases in Chile after 2004.

²⁷In 2015, United Nations member states agreed to work toward universal health coverage by 2030.

age group.

Using rich administrative data and the staggered coverage of disease-age groups, we showed that this reform led to a 4.4% decrease in deaths, implying that 1,678 deaths per year were averted thanks to this policy. This result is robust to several specification checks, and it is not driven by disease-specific shocks or a shift in healthcare resources from non-covered to covered diseases. We also show that the reform led to a larger decrease in mortality in diseases more amenable to care and among inpatients at public hospitals. It also increased inpatient surgeries, especially for polytraumatized inpatients.

Importantly, the Chilean reform was highly cost-effective. Using the median value of a statistical life in Chile (Mardones and Riquelme, 2018; Parada-Contzen, 2019), we calculate benefits of around USD \$5.7 billion per year. To proxy costs, we leverage the surge in the value-added tax that funded this program (Missoni and Solimano, 2010), which increased revenues by about USD \$1.2 billion in 2004. Based on these numbers, we conclude that the benefits outweighed the costs by a factor of four. Furthermore, a back-of-the-envelope calculation suggests that this reform increased life expectancy by 0.39 years (as of 2003, before implementation), a significant effect that would have taken people forward to the mortality conditions of 2005, when life expectancy was 77.78 years.²⁸

Countries may follow different paths to improve their healthcare systems, depending on their economic and historical contexts (Lagomarsino et al., 2012; Atun et al., 2015; Reich et al., 2016). Nonetheless, we hope that the disease-specific health insurance reform that we studied here can inform researchers and policymakers alike worldwide.

²⁸For the interested reader, Appendix B offers details on these back-of-the-envelope calculations.

References

- Abadie, A., A. Diamond, and J. Hainmueller (2010). Synthetic control methods for comparative case studies: Estimating the effect of california's tobacco control program. *Journal of the American statistical Association* 105(490), 493–505.
- Abadie, A., A. Diamond, and J. Hainmueller (2015). Comparative politics and the synthetic control method. *American Journal of Political Science* 59(2), 495–510.
- Alonso, F., C. Nazzari, F. Cerecera, and J. I. Ojeda (2019). Reducing health inequalities: comparison of survival after acute myocardial infarction according to health provider in chile. *International Journal of Health Services* 49(1), 127–141.
- Arroyave, I., D. Cardona, A. Burdorf, and M. Avendano (2013, mar). The impact of increasing health insurance coverage on disparities in mortality: Health care reform in Colombia, 1998-2007. *American Journal of Public Health* 103(3).
- Atun, R., L. O. M. De Andrade, G. Almeida, D. Cotlear, T. Dmytraczenko, P. Frensz, P. Garcia, O. Gómez-Dantés, F. M. Knauth, C. Muntaner, et al. (2015). Health-system reform and universal health coverage in latin america. *The Lancet* 385(9974), 1230–1247.
- Basu, S., J. Andrews, S. Kishore, R. Panjabi, and D. Stuckler (2012). Comparative performance of private and public healthcare systems in low-and middle-income countries: a systematic review. *PLoS medicine* 9(6), e1001244.
- Bilal, U., M. Alazraqui, W. T. Caiaffa, N. Lopez-Olmedo, K. Martinez-Folgar, J. J. Miranda, D. A. Rodriguez, A. Vives, and A. V. Diez-Roux (2019, dec). Inequalities in life expectancy in six large Latin American cities from the SALURBAL study: an ecological analysis. *The Lancet Planetary Health* 3(12), e503–e510.
- Bitran, R. (2013). Explicit health guarantees for chileans: the auge benefits package.
- Black, B. S., A. Hollingsworth, L. Nunes, and K. Simon (2019). *The effect of health insurance on mortality: power analysis and what we can learn from the affordable care act coverage expansions*. National Bureau of Economic Research Cambridge (MA).
- Borgschulte, M. and J. Vogler (2020, jul). Did the ACA Medicaid expansion save lives? *Journal of Health Economics* 72.
- Callaway, B. and P. H. Sant'Anna (2021). Difference-in-differences with multiple time periods. *Journal of Econometrics* 225(2), 200–230.
- Casparie, A. (1991). Guidelines to shape clinical practice. the role of medical societies: the dutch experience in comparison with recent developments in the american approach. *Health Policy* 18(3), 251–259.
- Cid Pedraza, C., C. A. Herrera, L. Prieto Toledo, and F. Oyarzún (2015). Mortality outcomes in hospitals with public, private not-for-profit and private for-profit ownership in chile 2001–2010. *Health policy and planning* 30(suppl_1), i75–i81.


- Clinicas de Chile (2016). Dimensionamiento del Sector de Salud Privado de Chile: Actualización a Cifras 2016. Technical report.
- De Chaisemartin, C. and X. d’Haultfoeuille (2020). Two-way fixed effects estimators with heterogeneous treatment effects. *American Economic Review* 110(9), 2964–96.
- Dicker, R. C., F. Coronado, D. Koo, and R. G. Parrish (2006). Principles of epidemiology in public health practice; an introduction to applied epidemiology and biostatistics.
- Dixon, J. and H. G. Welch (1991). Priority setting: lessons from oregon. *The Lancet* 337(8746), 891–894.
- Erazo, Á. (2011). La protección social en Chile el plan auge: Avances y desafíos.
- Finkelstein, A., N. Mahoney, and M. J. Notowidigdo (2018). What does (formal) health insurance do, and for whom? *Annual Review of Economics* 10, 261–286.
- Frenz, P., I. Delgado, J. S. Kaufman, and S. Harper (2014, sep). Achieving effective universal health coverage with equity: evidence from Chile. *Health policy and planning* 29(6), 717–731.
- Goldin, J., I. Z. Lurie, and J. McCubbin (2020, dec). Health Insurance and Mortality: Experimental Evidence from Taxpayer Outreach. *The Quarterly Journal of Economics* 136(1), 1–49.
- Gonzalez, F., L. R. Martinez, P. Muñoz, and M. Prem (2022). Does higher education reduce mortality? evidence from a natural experiment.
- Government of Chile (2010). Approves general technical standard on the use of “hospital discharge statistical report” form for producing statistical information on hospital discharge causes and related variables. Decreto 1671 Exento, Ministerio de Salud, Gobierno de Chile.
- Government of Chile (2016). Technical guidelines on health information standards. Decreto 643 Exento, Ministerio de Salud, Gobierno de Chile.
- Government of Chile (2021). Functional classification of the total central government expenditure 1990-2019. Dirección de Presupuestos, Gobierno de Chile.
- Gruber, J. and B. D. Sommers (2019, sep). The Affordable Care Act’s Effects on Patients, Providers and the Economy: What We’ve Learned So Far. *Journal of Policy Analysis and Management* 38(4), 1028–1052.
- Kline, P. (2011). Oaxaca-blinder as a reweighting estimator. *American Economic Review* 101(3), 532–537.
- Lagomarsino, G., A. Garabrant, A. Adyas, R. Muga, and N. Otoo (2012). Moving towards universal health coverage: health insurance reforms in nine developing countries in Africa and Asia. *The Lancet* 380(9845), 933–943.

- Mackenbach, J. P., Y. Hu, B. Artnik, M. Bopp, G. Costa, R. Kalediene, P. Martikainen, G. Menvielle, B. H. Strand, B. Wojtyniak, et al. (2017). Trends in inequalities in mortality amenable to health care in 17 european countries. *Health Affairs* 36(6), 1110–1118.
- Mardones, C. and M. Riquelme (2018). Estimation of the value of statistical life in chile and extrapolation to other latin american countries. *Latin American Research Review* 53(4), 815–830.
- McCrary, J. (2007). The effect of court-ordered hiring quotas on the composition and quality of police. *American Economic Review* 97(1), 318–353.
- Mena, G. E., P. P. Martinez, A. S. Mahmud, P. A. Marquet, C. O. Buckee, and M. Santilana (2021). Socioeconomic status determines covid-19 incidence and related mortality in santiago, chile. *Science* 372(6545), eabg5298.
- Mikkelsen, L., D. E. Phillips, C. AbouZahr, P. W. Setel, D. De Savigny, R. Lozano, and A. D. Lopez (2015). A global assessment of civil registration and vital statistics systems: monitoring data quality and progress. *The Lancet* 386(10001), 1395–1406.
- Miller, S., N. Johnson, and L. R. Wherry (2021). Medicaid and Mortality: New Evidence from Linked Survey and Administrative Data*. *The Quarterly Journal of Economics*.
- MINSAL (2004). Documento para la aplicación del sistema auge en las redes de atención del sistema nacional de servicios de salud.
- Missoni, E. and G. Solimano (2010). Towards universal health coverage: the chilean experience. *World health report*.
- Moreno-Serra, R. and P. C. Smith (2012). Does progress towards universal health coverage improve population health? *The Lancet* 380(9845), 917–923.
- Murray, C. J., S. C. Kulkarni, C. Michaud, N. Tomijima, M. T. Bulzacchelli, T. J. Iandiorio, M. Ezzati, M. Rahbari, S. Rahlfs, E. Jortzik, I. Bogeski, and K. Becker (2006, mar). Eight Americas: Investigating mortality disparities across races, counties, and race-counties in the United States. *PLoS Medicine* 12(4).
- Nazzari, C., F. Lanús, M. L. Garmendia, C. Bugueño, E. Mercadal, E. Garcés, P. Yovaninich, and P. Sanhueza (2013, aug). [Universal health coverage and accomplishment of secondary prevention goals among patients with acute myocardial infarction]. *Revista medica de Chile* 141(8), 977–986.
- Neilson, C., D. Contreras, R. Cooper, and J. Hermann (2008). The dynamics of poverty in chile. *Journal of Latin American Studies* 40(2), 251–273.
- Newhouse, J. P., R. C. I. E. Group, and I. E. G. Staff (1993). *Free for all?: lessons from the RAND health insurance experiment*. Harvard University Press.
- Nolan, A., P. May, S. Matthews, C. Normand, R. A. Kenny, and M. Ward (2022). Public health insurance and mortality in the older population: Evidence from the irish longitudinal study on ageing. *Health Policy* 126(3), 190–196.


- Nolte, E. and M. McKee (2003, sep). Measuring The Health Of Nations: Analysis Of Mortality Amenable To Health Care. *BMJ: British Medical Journal* 327(7424), 1129–1132.
- Nolte, E. and M. McKee (2011). Variations in amenable mortality—Trends in 16 high-income nations. *Health Policy* 103(1), 47–52.
- Parada-Contzen, M. V. (2019). The value of a statistical life for risk-averse and risk-seeking individuals. *Risk Analysis* 39(11), 2369–2390.
- Paraje, G. and A. Infante (2015). La reforma auge 10 años después. *Documento de Trabajo*.
- Pardo, C. (2019). Health care reform, adverse selection and health insurance choice. *Journal of health economics* 67, 102221.
- Parker, S. W., J. Saenz, and R. Wong (2018, feb). Health Insurance and the Aging: Evidence From the Seguro Popular Program in Mexico. *Demography* 55(1), 361–386.
- Ramos, P., P. Juan, L. Ottolino, R. Pablo, A. Muñoz, A. Carolina, C. Ruiz, E. José, P. Arenas, E. Claudia, et al. (2021). Primer registro de trauma en Chile. análisis de 2 años en un hospital público. *Revista de cirugía* 73(1), 59–65.
- Reich, M. R., J. Harris, N. Ikegami, A. Maeda, C. Cashin, E. C. Araujo, K. Takemi, and T. G. Evans (2016). Moving towards universal health coverage: lessons from 11 country studies. *The Lancet* 387(10020), 811–816.
- Rios-Avila, F. (2022). Jwdid: Stata module to estimate difference-in-difference models using mundlak approach.
- Sabik, L. M. and R. K. Lie (2008). Priority setting in health care: Lessons from the experiences of eight countries. *International Journal for equity in health* 7, 1–13.
- Sommers, B. D. (2017, jul). State medicaid expansions and mortality, revisited: A cost-benefit analysis. *American Journal of Health Economics* 3(3), 392–421.
- Sommers, B. D., S. K. Long, and K. Baicker (2014). Changes in mortality after Massachusetts health care reform : A quasi-experimental study. *Annals of Internal Medicine*.
- Sun, L. and S. Abraham (2021). Estimating dynamic treatment effects in event studies with heterogeneous treatment effects. *Journal of Econometrics* 225(2), 175–199.
- The Lancet (2019). Ensuring and measuring universality in UHC. *The Lancet* 393(10166), 1.
- Tobias, M. and L.-C. Yeh (2009). How much does health care contribute to health gain and to health inequality? Trends in amenable mortality in New Zealand 1981–2004. *Australian and New Zealand Journal of Public Health* 33(1), 70–78.
- Vargas, V. and S. Poblete (2008). Health prioritization: the case of Chile. *Health affairs* 27(3), 782–792.

- Weber, A. and M. Clerc (2017). Deaths amenable to health care: Converging trends in the eu? *Health Policy* 121(6), 644–652.
- WHO (2020). Who methods and data sources for country-level causes of death 2000-2019. *Department of Data and Analytics (DNA) Division of Data. WHO, Geneva.*
- Wooldridge, J. M. (2021). Two-way fixed effects, the two-way mundlak regression, and difference-in-differences estimators. *Available at SSRN 3906345.*
- Wooldridge, J. M. (2022). Simple approaches to nonlinear difference-in-differences with panel data. *Available at SSRN 4183726.*


Figure 1: Change in Deaths for Each GES Expansion




(a) 2004 Expansion



(b) 2005 Expansion




(c) 2006 Expansion



(d) 2007 Expansion


Notes: This figure shows the change in deaths for both the diseases covered by each GES expansion and the diseases never covered by the GES reform. All changes in deaths are reported in percentages and calculated with respect to the year before each expansion. The vertical solid yellow line represents one year before the expansion. The vertical dashed red line represents the first year of the expansion.

Figure 2: Event Studies: GES Impact on Deaths



(a) All Deaths


(b) All Deaths (7-year window)



(c) In-Hospital Deaths


Notes: This figure shows the results obtained from estimating the dynamic difference-in-differences using the count of deaths as the dependent variable in a Poisson regression. For figures in panel (a) and (b) We used data from 1997-2014 available in the death records, and we binned up endpoints for (a). In panel (c) we use data from 2001-2010 available in the discharged records. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Each RR is capturing the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression.

Figure 3: Event Study: GES Impact on More and *Less* Amenable Deaths




Notes: This figure shows the results obtained from estimating the dynamic difference-in-differences presented in equation (3) using the count of deaths as the dependent variable in a Poisson regression. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Panel (a) shows the event study for the set of deaths more amenable to health care (Nolte and McKee, 2011; Sommers et al., 2014). Panel (b) shows the event study for the set of deaths less amenable to health care. Less amenable deaths does not mean they cannot be impacted by health care, only that these deaths are likely to be less responsive to health care coverage than other causes. Each RR is capturing the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. For details about the Amenable classification, see Appendix Table A.5.

Figure 4: Sensitivity of the Impact on Death to Targeted Diseases




Notes: This figure shows the results obtained from estimating (several times) the dynamic difference-in-differences presented in equation (3) using the count of deaths as the dependent variable in a Poisson regression. Each point estimate and confidence interval comes from a regression in which we remove one treatment cell at a time, as indicated per the x-axis. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Each RR is capturing the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression.

Figure 5: Change in Deaths for Never-Covered Diseases in Chile and Latin America



(a) Yearly change in deaths



(b) Synthetic Control

Notes: This figure shows the time trends of deaths in uncovered diseases for different countries. Panel (a) report the percentage changes in deaths. The weighted average line shows the sum of countries' deaths using their contribution to total deaths (across countries) as weights. Panel (b) shows the result from a synthetic control analysis that uses log deaths in non-covered diseases as the main outcome. The vertical dashed red line represents the year the reform coverage started in Chile. Selected countries are those with high-quality mortality data under the World Health Organization classification. See the main text for details.

Table 1: GES Impact on Deaths

	Main		Type of death		
	All deaths	Ever covered	More amenable	Less amenable	In Hospital
	(1)	(2)	(3)	(4)	(5)
After GES Expansion	-0.044*** (0.014)	-0.040*** (0.010)	-0.071*** (0.026)	-0.028* (0.016)	-0.069*** (0.020)
No. Deaths	521,300	264,974	96,966	424,334	172,940
No. Deaths ∈ covered diseases (year before coverage)	38,129	38,129	9,167	28,962	10,773
Total No. disease-age cells (obs.)	99,146	24,906	18,236	80,910	81,654

Notes: This table shows the results obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The RRs captures the average effect for all groups of diseases after they started to be covered. Less amenable deaths do not mean they cannot be impacted by health care, only that these deaths are likely to be less responsive to health care coverage than other causes. The Poisson estimation drops disease-age cells with all zero outcomes in the study period. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table 2: Heterogeneous Impact on Deaths

	Sex		Age Group			Inpatients by Type of Hospital		
	Female	Male	0-49	50-79	80+	All	Public	Private
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
After GES Expansion	-0.052*** (0.017)	-0.038*** (0.014)	-0.082*** (0.022)	-0.047** (0.018)	-0.022 (0.029)	-0.069*** (0.020)	-0.073*** (0.021)	-0.023 (0.029)
No. Deaths	226,327	294,973	89,850	252,845	178,605	172,940	155,097	17,843
No. Deaths ∈ covered diseases (year before coverage)	16,819	21,310	5,611	19,015	13,503	10,773	9,683	1,090
Total No. disease-age cells (obs.)	77,145	80,558	42,145	36,415	20,586	81,654	78,139	30,850

Notes: This table shows the results obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The RRs captures the average effect for all groups of diseases after they started to be covered. The Poisson estimation drops disease-age cells with all zero outcomes in the study period. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table 3: GES Impact on Inpatient Surgeries

	Sex			Type of Hospital		Polytraumatized	
	All	Female	Male	Public	Private	Yes	No
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
After GES Expansion	0.151*** (0.032)	0.126*** (0.028)	0.200*** (0.041)	0.215*** (0.036)	0.004 (0.030)	0.339*** (0.065)	0.056** (0.029)
No. Surgeries	761,472	385,206	376,266	540,618	220,854	647,088	690,943
No. Surgeries ∈ covered diseases (year before coverage)	18,718	8,083	10,635	13,444	5,274	6,341	12,377
Total No. disease-age cells (obs.)	105,510	84,560	84,296	94,385	73,134	90,012	97,558

Notes: This table shows the results obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions using inpatient records. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The RRs captures the average effect for all groups of diseases after they started to be covered. The Poisson estimation drops disease-age cells with all zero outcomes in the study period. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table 4: GES Impact on Deaths Using WHO Mortality Database

	Diagnoses-age Categories				
	All	Ever covered			Non-covered
	Chile	Chile	Other countries	All countries	All countries
	(1)	(2)	(3)	(4)	(5)
After GES Expansion	-0.036** (0.015)	-0.039*** (0.011)	-0.010 (0.009)	-0.010 (0.009)	
After GES Expansion × Chile				-0.029** (0.015)	
After 2004 × Chile					0.023 (0.021)
Total No. disease-age cells (obs.)	83,390	16,520	125,678	142,198	1,045,860

Notes: This table shows the results from different Poisson regressions using death counts from the WHO Mortality dataset. All regressions control for disease-age cell fixed effects and year fixed effects. In addition, columns (3) and (4) use disease-age cell fixed effects, and year-fixed effects interacted with country-fixed effects. Column (1) considers data for Chile, including covered and non-covered diseases. Column (2) considers data for Chile, including only ever covered diseases. Columns (3), (4), and (5) also use data from other countries; columns (3) and (4) include only covered diseases while column (5) includes only non-covered diseases. All coefficients correspond to percent changes by subtracting one from the rate ratio (RR), i.e., $exp(\beta) - 1$. Standard errors are clustered at the level of treatment: disease-age in columns (1) and (2), diseases-age-country in columns (3) and (4), and disease-age-Chile in column (5). Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Online Appendix

The Impact of Disease-Specific Health Insurance Reform on Mortality

Felipe Menares and Pablo Muñoz

List of Figures

1	Change in Deaths for Each GES Expansion	28
2	Event Studies: GES Impact on Deaths	29
3	Event Study: GES Impact on More and <i>Less</i> Amenable Deaths	30
4	Sensitivity of the Impact on Death to Targeted Diseases	31
5	Change in Deaths for Never-Covered Diseases in Chile and Latin America	32
A.1	Protocol to Record Deaths	39
A.2	Age Standardized Cause-Specific Death Rate	40
A.3	Population Pyramids	41
A.4	Event Study: GES Impact on Deaths Alternative Models	42
A.5	Event Study: GES Impact on Deaths, by Expansion, Using Alternative Estimation Method	43
A.6	Event Study: GES Impact on Deaths, by Expansion	44
A.7	Event Study: GES Impact on Inpatient Surgeries	45
A.8	Sensitivity of the Impact on Surgeries to Targeted Diseases	46

List of Tables

1	GES Impact on Deaths	33
2	Heterogeneous Impact on Deaths	34
3	GES Impact on Inpatient Surgeries	35
4	GES Impact on Deaths Using WHO Mortality Database	36
A.1	Health Related Problems: Pilot 2004	47

A.2	Health Related Problems: 2005 Expansion	47
A.3	Health Related Problems: 2006 Expansion	48
A.4	Health Related Problems: 2007 Expansion	48
A.5	Definitions of Deaths More Amenable to Health Care	49
A.6	Targeted Diseases, Targeted Cells (Disease-Age Groups), and the Total Number of Deaths	50
A.7	Deaths Covered by ICD10 Chapters	51
A.8	Deaths Covered by Year	52
A.9	Deaths Covered by Age Group	53
A.10	Robustness of GES Impact on Deaths to Alternative Models	54
A.11	Pre-treatment Characteristics Between Covered and Non-covered Cells	55
A.12	GES Impact on Deaths by GES Expansion and Among Ever Covered	56
A.13	GES Impact on In-Hospital Deaths by Type of Health Care Provider Removing the 2004 (Pilot) Expansion	57
A.14	GES Impact on Deaths by Major Geographic Areas	58
A.15	GES Impact on Deaths Using Alternative Amenable Death Classifications	59
A.16	GES Impact on In-Hospital Deaths by Type of Insurance	60
C.1	GES Impact on Household Finance	65

Appendix A: Additional Figures and Tables

Figure A.1: Protocol to Record Deaths

Figura 1. Sección 3 “Causa de la muerte”, del formulario del Certificado Médico de Defunción vigente en Chile.


3.- CAUSA DE LA MUERTE. En caso de defunción fetal especifique la causa, no anote MORTINATO.		DURACIÓN ENFERMEDAD
CAUSA INMEDIATA: (Enfermedad o condición que produjo directamente la muerte)		
a) «Debida a» o «Como consecuencia de»		
CAUSAS ORIGINARIAS: (Enfermedades, lesiones y tipo de accidente, suicidio u homicidio que ocasionó la causa inmediata)		
b) «Debida a» o «Como consecuencia de»		
c)		
ESTADOS MORBOSOS CONCOMITANTES, (Contribuyentes a la defunción pero fuera de la cadena causal)		

El fin de las estadísticas de causas de muerte es contar con información que permita prevenir la muerte, para lo cual es necesario identificar aquella causa que dio origen a la cadena de eventos que condujo a la muerte y que se tabulará como la *causa básica* de defunción, definida como:

“(a) la **enfermedad o lesión** que **inició** la cadena de acontecimientos patológicos que condujeron directamente a la muerte, o
 (b) las circunstancias del **accidente o violencia** que produjo la lesión fatal”.


Notes: This figure shows an excerpt from the document “Manual of the Correct Filling of the Medical Certificate of Death” (Antini, 2020). It reads: *The purpose of statistics on causes of death is to have information that allows death to be prevented, for which it is necessary to identify the cause that gave rise to the chain of events that led to death and that will be tabulated as the basic cause of death.* Thus, causes (ICD-10 codes) recorded in our data should reflect the original cause of death.

Figure A.2: Age Standardized Cause-Specific Death Rate




Notes: This figure shows the decrease in cause-specific death rates for each group of treated diseases; in this case, all rates are standardized using the 2001 age distribution to account for the age structure of the population. To adjust death rates, we proceed in the following way: i) we calculate crude death rates for age x as the number of deaths for each group of disease-population of age x divided by the population of age x , where x stands for 5-year age groups (i.e., 0, 1-4 years, 5-9 years, ..., 85-99 years, and greater than 100 years); ii) we multiply the ratio obtained in step i) by the population share in 2001; and finally, iii) we sum across all the weighted age-specific shares obtained in step ii). The number of treated diseases in each group (“Expanders”) is listed in parentheses. Vertical solid yellow lines represent one year before the expansion. Vertical dashed lines represent the year of each of the expansions. All is based on data from the Death Registry, Vital Statistics, Census, and GES eligibility rules.

Figure A.3: Population Pyramids



(a) 2000, Pop: 15,323,350


(b) 2010, Pop: 17,062,531



(c) 2020, Pop 19,611,208


Notes: This figure shows population pyramids for Chile in the years 2000, 2010, and 2020. Source: Pyramids.net.

Figure A.4: Event Study: GES Impact on Deaths Alternative Models




Notes: This figure shows the results obtained from estimating the dynamic difference-in-differences presented in equation (3) using the count of deaths as the dependent variable in a Poisson compared to a Negative Binomial regression. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Each RR is capturing the effect each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. The negative Binomial model was estimated using R's fixest package

Figure A.5: Event Study: GES Impact on Deaths, by Expansion, Using Alternative Estimation Method




Notes: These figures display the point estimates and 95% confidence intervals obtained from a Poisson model that is robust even if the treatment effects are heterogeneous over time or across groups. Specifically, we follow [Wooldridge \(2021\)](#) and estimate a Poisson regression saturated with the interaction of all treatment cohorts (GES expansions) and event time dummies. The regression includes cell and year-fixed effects. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Coefficients capture the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression.

Figure A.6: Event Study: GES Impact on Deaths, by Expansion




Notes: These figures show the coefficients obtained from estimating the dynamic difference-in-differences presented in equation (3). Each regression considers each expansion independently using never treated cells. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Coefficients capture the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression.


Figure A.7: Event Study: GES Impact on Inpatient Surgeries



(a) All




(b) Public Hospitals



(c) Private Hospitals

Notes: These figures show the results obtained from estimating the dynamic difference-in-differences presented in equation (3) using the count of in-hospital deaths and in-hospital surgeries as dependent variables in Poisson regressions. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Each RR captures the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression.

Figure A.8: Sensitivity of the Impact on Surgeries to Targeted Diseases



Notes: This figure shows the results obtained from estimating (several times) the dynamic difference-in-differences presented in equation (3) using the count of surgeries as the dependent variable in a Poisson regression. Each point estimate and confidence interval comes from a regression in which we remove one treatment cell at a time, as indicated per the x-axis. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. The relative change reported in the y-axis corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $\exp(\beta_k) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. Each RR is capturing the effect of each period relative to one year before each group of diseases started to be covered. 95% confidence intervals for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression.

Table A.1: Health Related Problems: Pilot 2004

Health Related Problem	Deaths	%
Myocardial Infarction (Heart attack)	41,358	72.32
Breast cancer (15+ years old)	7,753	13.56
Lymphoma (15+ years old)	3,813	6.67
HIV/AIDS	2,948	5.15
Testicular cancer (15+ years old)	665	1.16
Diabetes mellitus, types 1	219	0.38
Psychosis (severe psychiatric disorders)	176	0.31
Spinal Dysraphism	161	0.28
Hip replacement (65+ years old)	50	0.09
Cleft lip/palate	45	0.08
Total	57,188	100.00

Notes: This table shows deaths for the health-related problems included in the 2004 pilot between 2001 and 2010. Diseases with zero deaths in the period are not included.

Table A.2: Health Related Problems: 2005 Expansion

Health Related Problem	Deaths	%
Pneumonias in older adults (65+ years old)	19,559	27.61
Diabetes mellitus, types 2	19,589	27.65
Arterial hypertension (15+ years old)	18,418	26.00
Heart Conduction System (15+ years old)	10,666	15.06
Prematurity	1,823	2.57
Acute respiratory infections (5- years old)	700	0.99
Epilepsy (between 1 and 15 years old)	88	0.12
Total	70,843	100.00

Notes: This table shows deaths for the health-related problems included in the 2005 Expansion between 2001 and 2010. Diseases with zero deaths in the period are not included.

Table A.3: Health Related Problems: 2006 Expansion

Health Related Problem	Deaths	%
Ischemic stroke (15+ years old)	24,402	30.60
Stomach cancer	21,851	27.40
Chronic obstructive pulmonary disease	19,586	24.56
Prostate cancer (15+ years old)	11,115	13.94
Respiratory distress in new-born	1,171	1.47
Cholecystostomy (between 35 to 49 years old)	1,034	1.30
Benign hypertrophy of the prostate	557	0.70
Hemophilia	25	0.03
Bronchial Asthma (15- years old)	9	0.01
Total	79,750	100.00

Notes: This table shows deaths for the health-related problems included in the 2006 Expansion between 2001 and 2010. Diseases with zero deaths in the period are not included.

Table A.4: Health Related Problems: 2007 Expansion

Health Related Problem	Deaths	%
Polytrauma with or without medullary lesion	30,096	52.62
Aneurysms	16,252	28.42
Primary brain tumors (15+ years old)	4,133	7.23
Leukemia (15+ years old)	3,811	6.66
Major burns	2,000	3.50
Rheumatoid arthritis	773	1.35
Cystic fibrosis	118	0.21
Alcohol/drug dependence (20- years old)	5	0.01
Osteoarthritis (Hip and Knee) (55+ years old)	3	0.01
Total	57,191	100.00

Notes: This table shows the health-related problems included in the 2007 Expansion between 2001 and 2010. Diseases with zero deaths in the period are not included.

Table A.5: Definitions of Deaths More Amenable to Health Care

Condition(s)	ICD-10 Codes	<i>Nolte & McKee</i>	<i>Sommers</i>	<i>Ours</i>
Infectious & Parasitic Diseases (ALL)	A00-B99		X	
-Tuberculosis	A16-19, B90	X	X	X
-Other specific infections (diphtheria, tetanus, septicemia, poliomyelitis, whooping cough, measles)	A00-09 (age 0-14), A33, A35-36, A37 (age 0-14), A40-41, A80, B05 (age 1-14)	X	X	X
Neoplasms (ALL)	C00-D48		X	
-Malignant neoplasm of colon and rectum	C18-C21	X	X	X
-Malignant neoplasm of skin	C44	X	X	X
-Malignant neoplasm of breast	C50	X	X	X
-Malignant neoplasm of cervix or uterus	C54-55 (age 0-44)	X	X	X
-Malignant neoplasm of testis	C62	X	X	X
-Hodgkin's disease	C81	X	X	X
-Leukemia	C91-C95 (≤ 45 years)	X	X	X
Disorders of thyroid gland	E00-E07	X	X	X
Diabetes Mellitus	E10-E14	X	X	X
Epilepsy	G40-G41	X	X	X
Chronic rheumatic heart diseases	I05-I09	X	X	X
Hypertensive diseases	I10-I13, I15	X	X	X
Ischemic heart diseases	I20-I25	X	X	X
Cardiomyopathy	I42		X	X
Atrial fibrillation and flutter	I48		X	X
Other cardiac arrhythmias	I49		X	X
Heart failure	I50		X	X
Cerebrovascular diseases	I60-I69	X	X	X
All respiratory diseases	J00-J98		X	
-Respiratory diseases (excl. pneumonia, influenza)	J00-09, J20-99 (age 1-14)	X		X
-Respiratory diseases	J10-18	X		X
Gastric and duodenal ulcers	K25-K27	X	X	X
Gastrojejunal ulcers	K28		X	X
Diseases of appendix	K35-K38	X	X	X
Hernia	K40-K46	X	X	X
Diseases of gallbladder and biliary tract	K80-K83	X	X	X
Acute pancreatitis	K85		X	X
Infections of the skin and subcutaneous tissue	L00-L08		X	X
Infectious arthropathies	M00-M02		X	X
Glomerular diseases	N00-N07	X	X	X
Renal tubulo-interstitial diseases	N10-N15		X	X
Renal failure	N17-N19	X	X	X
Unspecified contracted kidney, small kidney unknown cause	N26-N27	X		X
Hyperplasia of prostate	N40	X		X
Pregnancy, childbirth and the puerperium	O00-O99	X	X	X
Perinatal deaths, all causes (excl. stillbirths)	P00-P96	X		X
Congenital malformations	Q20-28	X		X
Misadventures to patients during surgical and medical care	Y60-Y69, Y83-Y84	X	X	X

Notes: This table shows the classification of conditions as more amenable to health care, according to different authors. *Nolte and McKee* corresponds to the classification used in [Nolte and McKee, 2011](#), *Sommers* corresponds to the classification used in [Sommers et al., 2014](#), and *Ours* corresponds to the classification used in this paper; which is as a combination of [Nolte and McKee, 2011](#) and [Sommers et al., 2014](#).

Table A.6: Targeted Diseases, Targeted Cells (Disease-Age Groups), and the Total Number of Deaths

	Deaths			In-Hospital	
	All	Amenable	Less amenable	Deaths	Surgeries
	(1)	(2)	(3)	(4)	(5)
Panel A: Diseases (ICD-10)					
Total	1,027	317	944	1,017	1,001
<i>Covered</i>	315	132	284	308	309
<i>Uncovered</i>	763	227	668	756	741
Panel B: Disease-Age Cells					
Total	10,982	2,057	8,925	9,027	11,555
<i>Covered</i>	3,558	778	2,780	2,872	3,349
<i>Uncovered</i>	7,424	1,279	6,145	6,155	8,206
Panel C: No. of Deaths					
Total	521,300	96,966	424,334	172,940	761,376
<i>Covered</i>	264,974	62,070	202,904	77,104	184,901
<i>Uncovered</i>	256,326	34,896	221,430	95,836	576,475
Total No. of disease-age cells (obs.)	99,146	18,236	80,910	81,654	105,543

Notes: This table describes the sample in terms of the number of targeted diseases (ICD-10), targeted group of disease-age (ICD-10-Age) cells, and the total number of deaths. The sample only includes diseases covered in the 2004 Pilot, in 2005, 2006, and 2007 expansions, and the never-covered diseases. Panel A shows counts for diseases. In this case, *Covered* and *Uncovered* do not add up since some diseases are in both groups because the coverage is for a specific group of ages. Panel B shows counts for disease-age cells. In this case, the number of disease-age cells is not balanced for some groups of ages. This is because Poisson estimation drops disease-age cells (obs.) with all zero outcomes in the period of study. Additionally, some groups of ages are not considered because they are covered as part of later expansions outside the window used in our study, e.g Bronchial Asthma was covered by the 2006 expansions for people below 15, but in 2010 expanded the age coverage for those above 15. Panel C shows counts for the total number of deaths in our sample. The total number of disease-age cells (obs.) is the result of the covered cells in the 7-year window and the uncovered cells in the period of study.

Table A.7: Deaths Covered by ICD10 Chapters

Chapters	All		Never Covered		Covered in Expansion:							
					2004		2005		2006		2007	
	N	%	N	%	N	%	N	%	N	%	N	%
Diseases of the circulatory system	184,292	35.35	73,196	39.72	41,358	22.44	29,084	15.78	24,402	13.24	16,252	8.82
Diseases of the respiratory system	61,987	11.89	22,187	35.79	-	-	20,205	32.60	19,595	31.61	-	-
Diseases of the digestive system	61,552	11.81	61,497	99.91	-	-	-	-	55	0.09	-	-
Neoplasms	60,535	11.61	6,415	10.60	12,231	20.20	-	-	33,945	56.07	7,944	13.12
Injury, poisoning and certain other consequences of external causes	58,608	11.24	26,512	45.24	-	-	-	-	-	0.00	32,096	54.76
Endocrine, nutritional and metabolic diseases	27,324	5.24	7,398	27.08	219	0.80	19,589	71.69	-	0.00	118	0.43
Certain infectious and parasitic diseases	15,756	3.02	12,754	80.95	2,948	18.71	54	0.34	-	0.00	-	-
Diseases of the genitourinary system	14,315	2.75	13,758	96.11	-	-	-	-	557	3.89	-	-
Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified	7,249	1.39	7,249	100.00	-	-	-	-	-	0.00	-	-
Diseases of the nervous system	7,209	1.38	7,108	98.60	13	0.18	88	1.22	-	0.00	-	-
Certain conditions originating in the perinatal period	5,391	1.03	2,612	48.45	-	0.00	1,823	33.82	956	17.73	-	-
Congenital malformations, deformations and chromosomal abnormalities	5,274	1.01	4,873	92.40	186	3.53	-	-	215	4.08	-	-
Mental, Behavioral and Neurodevelopmental disorders	3,741	0.72	3,560	95.16	176	4.70	-	-	-	0.00	5	0.13
Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism	2,928	0.56	2,896	98.91	7	0.24	-	-	25	0.85	-	-
Diseases of the skin and subcutaneous tissue	2,506	0.48	2,506	100.00	-	0.00	-	-	-	0.00	-	-
Diseases of the musculoskeletal system and connective tissue	2,353	0.45	1,525	64.81	50	2.12	-	-	-	0.00	778	33.06
Pregnancy, childbirth and the puerperium	276	0.05	276	100.00	-	0.00	-	-	-	0.00	-	-
Diseases of the eye and adnexa	4	0.00	4	100.00	-	0.00	-	-	-	0.00	-	-
Total	521,300	100	256,326	49.17	57,188	10.97	70,843	13.59	79,750	15.30	57,193	10.97

Notes: This table shows the number and percentage of deaths (from the deaths records), by reform coverage and ICD-10 chapter. We list the chapter's title according to the international version of the ICD-10, grouping deaths in our sample by the code range of each chapter.

Table A.8: Deaths Covered by Year

Year	All		Never Covered		Covered in Expansion:							
	N	%	N	%	2004		2005		2006		2007	
	N	%	N	%	N	%	N	%	N	%	N	%
2001	31,707	6.08	23,877	75.31	7,830	0.00	-	0.00	-	0.00	-	0.00
2002	40,757	7.82	23,626	57.97	8,017	22.36	9,114	22.36	-	0.00	-	0.00
2003	53,427	10.25	24,096	45.10	8,261	17.84	9,534	17.84	11,536	21.59	-	0.00
2004	62,829	12.05	25,036	39.85	7,965	16.56	10,404	16.56	11,505	18.31	7,919	12.60
2005	62,535	12.00	24,766	39.60	8,171	16.17	10,115	16.17	11,482	18.36	8,001	12.79
2006	61,961	11.89	24,747	39.94	8,256	15.80	9,791	15.80	11,185	18.05	7,982	12.88
2007	67,057	12.86	27,206	40.57	8,688	16.77	11,247	16.77	11,669	17.40	8,247	12.30
2008	56,484	10.84	26,546	47.00	-	18.83	10,638	18.83	11,017	19.50	8,283	14.66
2009	47,345	9.08	27,770	58.65	-	0.00	-	0.00	11,356	23.99	8,219	17.36
2010	37,198	7.14	28,656	77.04	-	0.00	-	0.00	-	0.00	8,542	22.96
Total	521,300	100	256,326	49.17	57,188	10.97	70,843	13.59	79,750	15.30	57,193	10.97

Notes: This table shows the number and percentage of deaths (from the deaths records), by reform coverage and year.

Table A.9: Deaths Covered by Age Group

Age Group	All		Never Covered		Covered in Expansion:							
	N	%	N	%	2004		2005		2006		2007	
					N	%	N	%	N	%	N	%
0-14	16,564	3.18	11,129	67.19	197	1.19	2615	15.79	1,265	7.64	1,358	8.20
15-49	73,286	14.06	39,961	54.53	7602	10.37	1749	2.39	3,504	4.78	20,470	27.93
50-54	22,464	4.31	12,275	54.64	3107	13.83	1192	5.31	1,921	8.55	3,969	17.67
55-59	27,969	5.37	14,986	53.58	4013	14.35	2033	7.27	2,946	10.53	3,991	14.27
60-64	35,865	6.88	18,405	51.32	5078	14.16	3198	8.92	4,808	13.41	4,376	12.20
65-69	43,777	8.40	20,802	47.52	5963	13.62	5185	11.84	7,309	16.70	4,518	10.32
70-74	55,351	10.62	25,095	45.34	7345	13.27	7841	14.17	10,658	19.26	4,412	7.97
75-79	67,419	12.93	29,973	44.46	7853	11.65	10759	15.96	14,012	20.78	4,822	7.15
80-84	68,060	13.06	31,035	45.60	6754	9.92	12192	17.91	13,906	20.43	4,173	6.13
85-89	58,242	11.17	27,259	46.80	5236	8.99	11751	20.18	11,046	18.97	2,950	5.07
90-94	36,864	7.07	17,492	47.45	2971	8.06	8572	23.25	6,256	16.97	1,573	4.27
95-99	12,967	2.49	6,573	50.69	913	7.04	3114	24.01	1,860	14.34	507	3.91
100+	2,472	0.47	1,341	54.25	156	6.31	642	25.97	259	10.48	74	2.99
Total	521,300	100.00	256,326	49.17	57,188	10.97	70843	13.59	79,750	15.30	57,193	10.97

Note: This table shows the number and percentage of deaths (from the deaths records), by reform coverage and age group. The 0-14 age group was combined because of the few deaths reported in the age groups used in the main analysis: newborns, 1-4 years, 5-9, and 10-14.

Table A.10: Robustness of GES Impact on Deaths to Alternative Models

	Non-linear		Linear	
	Poisson	Neg-Bin	Log	IHS
	(1)	(2)	(3)	(4)
After GES Expansion	-0.044*** (0.014)	-0.045*** (0.012)	-0.011* (0.006)	-0.015* (0.008)
Observations	99,146	99,146	99,146	99,146

Notes: This table shows the results obtained from variations of the staggered difference-in-differences model given by equation (1). Column (1) presents the estimates from our main model while column (2) presents the estimates from a negative binomial regression. Columns (3) and (4) show the results obtained from linear models (OLS). Log represents a logarithmic transformation of the outcome as $\ln(\text{deaths}+1)$. IHS stands for the Inverse Hyperbolic Sine transformation of the outcome. For the Poisson model (column 1), *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $\exp(\beta) - 1$. All regressions control for disease-age cell and year-fixed effects using the main sample. Standard errors are clustered at the level of treatment: disease-age cell. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table A.11: Pre-treatment Characteristics Between Covered and Non-covered Cells

	Level (2001)		Growth (2001-2003)			
	GES	Non-GES	GES	Non-GES	$\hat{\beta}$	p-value
	(1)	(2)	(3)	(4)	(5)	(6)
% Public Insurance	0.297	0.282	0.371	0.320	0.051	.089
% Private Insurance	0.078	0.046	0.045	0.038	0.007	.680
% High School	0.449	0.268	0.002	0.011	-0.009	.757
% Female	0.328	0.469	0.031	0.006	0.024	.344
% Married	0.359	0.380	-0.051	-0.064	0.013	.653
% Rural	0.099	0.160	-0.025	-0.022	-0.004	.817
% North	0.085	0.078	-0.018	-0.008	-0.010	.547
% Centre	0.159	0.155	-0.006	0.010	-0.016	.489
% Metro	0.462	0.367	0.019	-0.000	0.019	.524
% Center-South	0.200	0.245	-0.020	0.001	-0.021	.426
% South	0.084	0.137	0.013	-0.004	0.016	.371
% Austral	0.010	0.018	0.012	0.001	0.012	.164

Notes: This table shows pre-treatment characteristics from the death records of covered and non-covered cells. Columns (1) and (2) show the average of each characteristic among covered and non-covered cells in 2001. Columns (3) and (4) show the linear growth between 2001 and 2003 of each characteristic among covered and non-covered cells. Column (5) shows the coefficient obtained from a linear projection of growth on an indicator of GES coverage. Column (6) are the p-values associated with the column (5) coefficients.

Table A.12: GES Impact on Deaths by GES Expansion and Among Ever Covered

	Analysis Sample				
	Ever	Only Expansion:			
	GES	2004	2005	2006	2007
	(1)	(2)	(3)	(4)	(5)
After GES Expansion	-0.040*** (0.010)	-0.034 (0.025)	0.014 (0.036)	-0.089*** (0.025)	-0.058*** (0.017)
# Deaths	264,974	313,514	327,169	336,076	313,519
# Deaths Covered (as of 2003)	29,331	8,261	10,404	11,482	7,982
Total No. disease-age cells (obs.)	24,906	78,517	79,119	76,879	87,351

Notes: This table shows the coefficients obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions on the count of deaths. Column (1) only considers ever-covered diseases and leverages differences in the timing of adoption among them for identification. Columns (2)-(5) consider the impact of each expansion separately, using never covered diseases as controls. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The Poisson estimation drops disease-age cells with all zero outcomes in the period of study. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table A.13: GES Impact on In-Hospital Deaths by Type of Health Care Provider Removing the 2004 (Pilot) Expansion

	All	Type of Hospital	
	inpatients	Public	Private
	(1)	(2)	(3)
After GES Expansion	-0.074*** (0.023)	-0.079*** (0.024)	-0.031 (0.034)
# Deaths	161,269	145,224	16,045
# Deaths Covered (as of 2003)	6,078	5,541	537
Total No. disease-age cells (obs.)	78,343	75,042	29,291

Notes: This table shows the results obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions on inpatient records. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and if less than 1, indicates a decreased risk for the covered group. The RRs captures the average effect for all groups of diseases after they started to be covered. The Poisson estimation drops disease-age cells with all zero outcomes in the study period. Standard errors for RR are computed using the method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table A.14: GES Impact on Deaths by Major Geographic Areas

	North	Center	R.M.	Center-South	South	Austral
	(1)	(2)	(3)	(4)	(5)	(6)
After GES Expansion	-0.013 (0.024)	-0.069*** (0.018)	-0.003 (0.016)	-0.077*** (0.018)	-0.068*** (0.018)	-0.057 (0.043)
# Deaths	34,038	80,661	192,498	132,338	73,371	8,394
# Deaths Covered (as of 2003)	1,681	4,663	10,891	7,542	4,113	441
Total No. disease-age cells (obs.)	38,133	52,524	73,654	61,897	50,021	18,621

This table shows the results obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $\exp(\beta) - 1$. The interpretation of the value of a rate ratio of 0 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The RRs capture the average effect for all groups of diseases after they started to be covered. The Poisson estimation drops disease-age cells with all zero outcomes in the study period. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Geographic Areas are administrative regions grouped using the Ministry of Science and Technology definition. North: Arica y Parinacota, Tarapacá, Antofagasta, and Atacama; Center: Coquimbo and Valparaíso; Metro: Metropolitan Region; Center-South: O'Higgins, Maule, Ñuble and Biobío; South: La Araucanía, Los Ríos and Los Lagos. Austral: Aysen and Magallanes. The Metro area represents almost 40% of the population and includes the capital city. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table A.15: GES Impact on Deaths Using Alternative Amenable Death Classifications

	<i>Ours</i>		Nolte & McKee (2011)		Tobias & Yeh (2009)		European Union (2015)	
	Amenable	Non-Amenable	Amenable	Non-Amenable	Amenable	Non-Amenable	Amenable	Non-Amenable
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)
After GES Expansion	-0.071*** (0.026)	-0.028* (0.016)	-0.063** (0.026)	-0.029* (0.016)	-0.047** (0.022)	-0.025 (0.018)	-0.057** (0.024)	-0.026 (0.017)
# Deaths	96,966	424,334	86,324	434,976	134,481	386,819	106,780	414,520
# Deaths Covered (as of 2003)	7,693	21,638	7,121	22,210	12,741	16,590	8,807	20,524
Total No. disease-age cells (obs.)	18,236	80,910	15,538	83,608	20,346	78,800	22,216	76,930

Notes: This table shows the coefficients obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions for the count of more amenable and less amenable deaths, as classified by different authors. *Ours* corresponds to the classification used in our main analyses. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The coefficients capture the average effect for all groups of diseases after they started to be covered. The Poisson estimation drops disease-age cells with all zero outcomes in the period of study. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Table A.16: GES Impact on In-Hospital Deaths by Type of Insurance

	Insurance		Type of Public Insurance				
	Private	Public	A	B	C	D	NA
	(1)	(2)	(3)	(4)	(5)	(6)	(7)
After GES Expansion	-0.089*** (0.026)	-0.065*** (0.021)	-0.065** (0.025)	-0.069*** (0.025)	-0.097** (0.040)	-0.0531 (0.0385)	-0.0548 (0.0759)
# Deaths	19,628	153,635	61,816	69,980	7,791	11,474	2,574
# Deaths Covered (as of 2003)	971	6,971	2,811	3,381	298	370	111
Total No. disease-age cells (obs.)	33,433	77,745	58,475	51,182	21,935	24,552	10,873

Notes: This table shows the coefficients obtained from estimating the staggered difference-in-differences presented in equation (1) using Poisson regressions on inpatient records. All regressions control for disease-age cell and year-fixed effects. Standard errors are clustered at the level of treatment: disease-age cell. *After GES Expansion* corresponds to percent changes by subtracting 1 from the rate ratio (RR), i.e., $exp(\beta) - 1$. The interpretation of the value of a rate ratio of 1 indicates equal rates in the two groups (covered and non-covered), a rate ratio greater than 1 indicates an increased risk for the covered group, and, if less than 1, indicates a decreased risk for the covered group. The coefficients capture the average effect for all groups of diseases after they started to be covered. The Poisson estimation drops disease-age cells with all zero outcomes in the study period. Insurance information is only available from the inpatient records. Private and Public correspond to ISAPRE and FONASA, respectively. The type of Public Insurance corresponds to the four types of co-payment faced by the FONASA beneficiaries as a function of their income. Standard errors for RR are computed using the delta method for univariate transformations on the coefficient estimated from the Poisson regression. Significance levels: *** $p < 0.01$, ** $p < 0.05$, * $p < 0.1$.

Appendix B: The Valuation of Lives Saved

In this appendix, we present a back-of-the-envelope calculation on the impact of the GES reform on life expectancy, and we also show a simple cost-benefit analysis based on estimates of the value of statistical life and the cost of the reform.

Impact on life expectancy: Period Life expectancy at birth was 77.33 years in 2003, the pre-reform year for which official data is reported in detail. Notice that period life expectancy assumes that people live their entire life, from birth to death, under the mortality conditions of 2003 ([Human Mortality Database, 2022](#)). In other words, this indicator implicitly assumes that the benefits from the GES reform are experienced each year over and over again as a person gets older. Thus, based on our estimates, we apply the relative decrease in deaths to the age-specific mortality rates from the life table and then recalculate life expectancy, finding that the reform led to an increase of 0.39 years in terms of life expectancy as of 2003.²⁹ Such a decline would have taken people forward close to the mortality conditions of 2005, when life expectancy was 77.78 years. Therefore, we can say that the progress in life expectancy, which would typically take two years, was achieved before it would have been without the reform.

Cost-Benefit Analysis: The value of a statistical life (VSL) might be helpful to guide policymakers in their analysis of the benefits of the reform. VSL represents risk-money trade-offs for small changes in risk. Thus estimates are usually based on the extra wages that workers receive for facing increased fatality risk at work. For instance, a worker who receives extra pay of \$1,000 to face a risk of 1/10,000 has a value per unit risk (or VSL) of $\$1,000 / (1/10,000) = \10 million, regardless of age ([Viscusi, 2018](#)). The VSL varies with countries' income levels, as do many other expenditures. For Chile, in U.S. dollars of 2022, there are numbers ranging from \$0,50 to \$6,33 million depending on the method and purpose ([Mardones and Riquelme, 2018](#); [Parada-Contzen, 2019](#)). Using Chile's halfway point estimates -\$USD 3,419,185-, which represents two thirds of the GDP per capita in 2004, we can say that the 1,678 lives saved thanks to the GES reform (in one year) would be valued at USD \$4,182,772,414, approximately 8% of the GDP in 2003.³⁰

Evaluating the cost of measures taken to save people's lives is challenging. However, the tax reform implemented to fund the GES Program in 2003 brought USD \$1,224,506,697 in additional revenues after one year of its implementation. Therefore, we can say that the cost of the reform was approximately a third of the benefits that were brought because of the lives saved.

²⁹We compared our results using Table 1, column (1), and Table 2 columns (3-5) age-specific coefficients to compute the total and age-specific relative decrease in deaths, finding a 0.01 difference between them.

³⁰All values in U.S. dollars of 2022. Exchange rate used to convert from Chilean pesos to U.S. currency corresponds to the market-observed dollar rate exchange published by the Chilean Central Bank.

Appendix C: Reform Impact on Medical Visits and Household Finance

The existing literature has identified several financial outcomes that can be affected by health reforms (see [Finkelstein et al., 2018](#) for a review). For instance, health reforms can decrease out-of-pocket medical expenses, thus increasing household resilience to health and income shocks. Likewise, public insurance programs may decrease households' medical debt ([Gross and Notowidigdo, 2011](#); [Barcellos and Jacobson, 2015](#); [Mazumder and Miller, 2016](#)) and reliance on precautionary savings ([Starr-McCluer, 1996](#); [Gruber and Yelowitz, 1999](#)). In this section, we study these dimensions of household finance, although not exhaustively.

For this purpose, we leverage the main longitudinal survey in the country, known as the Social Protection Survey, or EPS by its acronym in Spanish. The survey is organized into modules, including demographics and health. While the EPS reports general questions for all household members, detailed questions related to health are only asked to the head of the household. Moreover, although the first survey was done in 2002, questions related to the GES reform are only available since 2009. Consequently, we construct a panel data set at the household-head level for our analysis using the years 2009, 2012, and 2015. For each household head, we observe their age, gender, educational attainment, type of health insurance, self-perception of health status, number of medical visits, total medical expenditures, and overall indebtedness. Importantly, we also know whether the respondent has been diagnosed with a specific health condition from a set of eleven (broad) diseases and whether she has benefited from GES coverage for said condition.³¹ Figure C.1 shows the share of respondents, by type of insurance, who report that GES covered their health condition. This figure highlights two facts consistent with the nature of the reform. First, coverage has been increasing over time. Second, there is no large difference between private and public insurance respondents.

We aim to study the impact of the expansions on healthcare access, out-of-pocket health expenditures, and overall indebtedness. To do so, we focus on respondents who report ever being diagnosed with a health condition and for them, we estimate the following model:

$$Y_{it} = \alpha + \rho_t + \beta \text{GES}_{it} + \gamma X_{it} + \varepsilon_{it}, \quad (4)$$

where Y_{it} is an outcome of respondent i at time t , ρ_t are survey year fixed effects, GES_{it} is an indicator that equals one if the respondent declares to have benefited from GES coverage for her health condition, and X_{it} is a vector of controls including age, age squared, self-perceived health status, type of insurance, gender, and education indicators (any college and any high school dummies). Finally, ε_{it} is an error term clustered at the survey's respondent level.

The parameter of interest is β , which under a (strong) conditional independence assumption, can be interpreted as the effect of GES coverage on the outcome of interest. Taking advantage of the panel structure of our data, we also estimate a more stringent specification, including person-fixed effects. In this case, β is identified under a strict exogeneity assumption.

³¹The set of health conditions includes: asthma, depression, diabetes, hypertension, heart-related problems, cancer, arthritis or arthrosis, renal disease, stroke, mental illness, and HIV/AIDS.


tion by leveraging variation in GES coverage across time. Naturally, given the short panel (3 survey years), controlling for time-invariant respondents' unobserved characteristics may come at the cost of exacerbating measurement error problems.

We study health and household finance outcomes. First, we focus on the number of medical visits during the past two years. Medical visits include general, specialty, and urgent consultations, as well as exam visits (e.g., X-rays, lab exams), surgeries, and hospitalizations. Second, we study out-of-pocket medical expenditures related to the aforementioned medical visits. Third, we look at indebtedness. Unfortunately, questions referring specifically to medical debt are not available in the survey. Thus, we construct a measure of indebtedness that considers loans from banks or financial institutions and loans from friends and informal institutions. We exclude auto loan and education loan debt to better approximate health-related debt.

Table C.1 presents our estimates of equation (4). Panel A focuses on the extensive margin, i.e., we construct the outcome variables as binary indicators that equal one if the respondent had *any* medical visit, had *any* medical expenditure, or held *any* debt. Columns 1 to 3 show a positive and statistically significant impact of GES coverage on the likelihood of reporting medical visits. Likewise, columns 4 to 6 show a negative and statistically significant effect of GES coverage on the likelihood of reporting any out-of-pocket medical expenditure. When looking at indebtedness, however, we do not find robust evidence of a significant impact on the likelihood of holding debt. Indeed, the negative impact of column 7 becomes positive and non-significant after the inclusion of controls and person-fixed effects. Focusing on our preferred specifications in columns 2 and 5, and relative to the mean among non-covered, the magnitude of these impacts is economically significant; respondents whose health condition was covered by GES are 46% more likely to report a medical visit and 26% less likely to report out-of-pocket medical expenditures.

In Panel B of Table C.1, we turn to the intensive margin, i.e., we construct the outcome variables as the log of the number of medical visits, the log of out-of-pocket medical expenditures (in 2022 USD), and the log of the amount of debt (in 2022 USD). As shown by the estimates, GES coverage had significant effects on the number of medical visits and the amount of out-of-pocket health spending. In this case, again, we cannot reject the null of a zero impact of GES coverage on people's indebtedness. In terms of magnitudes, respondents whose health condition was covered by GES have 40% more medical visits and spend 49% less on healthcare. All in all, these results suggest that the reform led to more medical care and less out-of-pocket spending among its beneficiaries.

Figure C.1: Share of Respondents With GES Coverage



Notes: This figure uses panel data from the EPS survey for the years 2009, 2012, and 2015. We focus on respondents who declare ever being diagnosed with asthma, depression, diabetes, hypertension, heart-related problems, cancer, arthritis or arthrosis, renal disease, stroke, mental illness, or HIV AIDS. Among them, we display the share (in percentual points) that reports that their illness was covered by GES, by type of insurance.

Table C.1: GES Impact on Household Finance

	Medical Visits			Medical Expenditures			Indebtedness		
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)
Panel A: Extensive Margin (Any)									
Declared to have benefited from GES coverage	0.043*** (0.003)	0.039*** (0.004)	0.028*** (0.007)	-0.170*** (0.007)	-0.130*** (0.008)	-0.073*** (0.011)	-0.030*** (0.006)	0.002 (0.006)	0.007 (0.008)
# Observations	18,769	15,954	14,238	18,769	15,954	14,238	18,769	15,954	14,238
# Individuals	10165	7489	5773	9402	7000	4534	10619	7489	6418
Mean Dep. Variable	0.852	0.830	0.845	0.493	0.503	0.487	0.155	0.151	0.153
Panel B: Intensive Margin (Log of)									
Declared to have benefited from GES coverage	0.477*** (0.017)	0.397*** (0.019)	0.247*** (0.026)	-0.504*** (0.066)	-0.486*** (0.073)	-0.333** (0.157)	-0.084 (0.065)	-0.048 (0.076)	0.243 (0.165)
# Observations	16,937	14,122	11,981	4,436	3,749	1,590	3,025	2,526	929
# Individuals.	10165	7489	5773	10165	7489	5773	10165	7489	5773
Mean Dep. Variable	11.95	11.73	11.76	644.6	635.6	784	4459	4692	5092
Year FE	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Controls	No	Yes	Yes	No	Yes	Yes	No	Yes	Yes
Person FE	No	No	Yes	No	No	Yes	No	No	Yes

Notes: This table uses panel data from the EPS survey for the years 2009, 2012, and 2015. We focus on respondents who declare ever being diagnosed with asthma, depression, diabetes, hypertension, heart-related problems, cancer, arthritis or arthrosis, renal disease, stroke, mental illness, or HIV/AIDS. The explanatory variable is an indicator that equals 1 if the respondent reports that GES covered her illness. *Medical Visits* corresponds to the number of medical visits during the past two years. *Medical Expenditures* corresponds to the total out-of-pocket medical expenses per visit among those who had at least one medical visit during the past two years. *Indebtedness* corresponds to loans from banks or financial institutions (excluding auto loan and education loan debt) and loans from friends and informal institutions. Both *Medical Expenditures* and *Indebtedness* are measured in 2022 USD. Controls include age, age squared, self-perceived health status, type of insurance, gender, and education indicators of any college and any high school. Standard errors are clustered at the respondent level. Significance levels: *** p<0.01, ** p<0.05, * p<0.1.

Appendix References

- ANTINI, C. (2020): “Manual del Correcto Llenado del Certificado Médico de Defunción,” *Escuela de Salud Pública, Universidad de Chile*.
- BARCELLOS, S. H. AND M. JACOBSON (2015): “The effects of Medicare on medical expenditure risk and financial strain,” *American Economic Journal: Economic Policy*, 7, 41–70.
- FINKELSTEIN, A., N. MAHONEY, AND M. J. NOTOWIDIGDO (2018): “What does (formal) health insurance do, and for whom?” *Annual Review of Economics*, 10, 261–286.
- GROSS, T. AND M. J. NOTOWIDIGDO (2011): “Health insurance and the consumer bankruptcy decision: Evidence from expansions of Medicaid,” *Journal of public Economics*, 95, 767–778.
- GRUBER, J. AND A. YELOWITZ (1999): “Public health insurance and private savings,” *Journal of Political Economy*, 107, 1249–1274.
- HUMAN MORTALITY DATABASE (2022): “Human Mortality Database,” .
- MARDONES, C. AND M. RIQUELME (2018): “Estimation of the value of statistical life in Chile and extrapolation to other Latin American countries,” *Latin American Research Review*, 53, 815–830.
- MAZUMDER, B. AND S. MILLER (2016): “The effects of the Massachusetts health reform on household financial distress,” *American Economic Journal: Economic Policy*, 8, 284–313.
- NOLTE, E. AND M. MCKEE (2011): “Variations in amenable mortality—Trends in 16 high-income nations,” *Health Policy*, 103, 47–52.
- PARADA-CONTZEN, M. V. (2019): “The Value of a Statistical Life for Risk-Averse and Risk-Seeking Individuals,” *Risk Analysis*, 39, 2369–2390.
- SOMMERS, B. D., S. K. LONG, AND K. BAICKER (2014): “Changes in mortality after Massachusetts health care reform : A quasi-experimental study,” *Annals of Internal Medicine*.
- STARR-McCLUER, M. (1996): “Health insurance and precautionary savings,” *The American Economic Review*, 86, 285–295.
- VISCUSI, W. K. (2018): “Pricing lives: International guideposts for safety,” *Economic Record*, 94, 1–10.
- WOOLDRIDGE, J. M. (2021): “Two-way fixed effects, the two-way mundlak regression, and difference-in-differences estimators,” *Available at SSRN 3906345*.